3.2.2: DVV Query

Please provide • E-copies of the grant award letters for research projects sponsored by government agencies for 2018-19 (Prof. Pinaki Majumdar, Dr. Vikram Gota, Dr.PrithaRay,DR.ALIASGAR V MOIYADI), 2016-17 (Dr. R. Badwe, Dr. Tejpal Gupta, Dr. Jyoti A Kode, Dr. Supriya Chopra, Dr. Vikram Gota, Dr.NavinKhattry, Dr. Amit Dutt, Dr. Manoj B Mahimkar), 2015-16 (Dr. Vivek G. Bhat, Dr. Jayant SastriGoda, Dr. Vikram Gota, Dr. Ashok Varma) and 2014-15 (DR. SANJAY GUPTA, DR. SUDHIR NAIR, Dr. NavinKhattry, Dr. Vikram Gota, Dr Manoj Mahimkar) and 2017-18 (Dr. Balasubramanian C, Dr. G. Ravi, Dr. PurviKikani, Prof. Shashank Chaturvedi, Dr. Tejpal Gupta, Dr. Sanjay Gupta)

Response: Grant award letters for DVV selected research projects are appended from page no. 2 onwards as indicated in the Table below, year wise from 2018-19 to 2014-15.

Sr No.	Awardee Name	Year	Location Page No.
1.	Prof. Pinaki Majumdar	2018-2019	2 to 12
2.	Dr. Vikram Gota	2018-2019	13 to 14
3.	Dr. Pritha Ray	2018-2019	15 to 16
4.	DR.ALIASGAR V MOIYADI	2018-2019	17 to 20
5.	Dr. Balasubramanian C	2017-2018	21-23
6.	Dr. G. Ravi	2017-2018	24-28
7.	Dr. PurviKikani	2017-2018	
8.	Prof. Shashank Chaturvedi	2017-2018	29
9.	Dr. Tejpal Gupta	2017-2018	30-33
10.	Dr. Sanjay Gupta	2017-2018	34
11.	Dr. R. Badwe	2016-2017	35
12.	Dr. Tejpal Gupta	2016-2017	36-43
13.	Dr. Jyoti A Kode	2016-2017	44-47
14.	Dr. Supriya Chopra	2016-2017	48-50
15.	Dr. Vikram Gota	2016-2017	51
16.	Dr. Navin Khattry	2016-2017	52-56
17.	Dr. Amit Dutt	2016-2017	57
18.	Dr. Manoj B Mahimkar	2016-2017	58-59
19.	Dr. Vivek G. Bhat	2015-2016	60-62
20.	Dr. Jayant Sastri Goda	2015-2016	63-64
21.	Dr. Vikram Gota	2015-2016	65
22.	Dr. Ashok Varma	2015-2016	66-71
23.	Dr. Sanjay Gupta	2014-2015	72
24.	Dr. Sudhir Nair	2014-2015	73-74
25.	Dr. Navin Khattry	2014-2015	75
26.	Dr. Vikram Gota	2014-2015	76-77
27.	Dr Manoj Mahimkar	2014-2015	78



STAMP DUTY

KARNATAKA

MEMORANDUM OF UNDERSTANDING

This binding Memorandum of Understanding ("MOU") is made at Bangalore on this ____ day of March 2017;

AMONGST

1. **INFOSYS FOUNDATION**, a non-profit organization having its office at Neralu, #1/2 (1878), 11th Main, 39th Cross, 4th T Block, Jayanagar, Bangalore - 560 011, Karnataka, India (hereinafter referred to as "**Foundation**", which expression shall, unless repugnant to the context or meaning thereof, include its successors and permitted assigns) of the **FIRST PART**;

AND

2. HARISH CHANDRA RESEARCH INSTITUTE, an autonomous organization having its office at Chhatnag Rpad, Jhusi, Allahabad-211 019, Uttar Pradesh, India (hereinafter referred to as "Grant Holder", which expression shall, unless repugnant to the context or meaning thereof, include its successors and permitted assigns) of the SECOND PART;

(Foundation and Grant Holder are referred to individually as "Party" and collectively as "Parties")

WHEREAS:

- A. Pursuant to Section 135 of the Companies Act, 2013, Infosys Limited (the "Company") in pursuance of its Corporate Social Responsibility Policy has decided to fulfil its CSR obligations via Foundation.
- B. Foundation shall oversee the CSR activities and has overall responsibility for identifying the areas of CSR activities, recommending the amount of expenditure to be incurred on the identified CSR activities, implementing the CSR policy and executing initiatives as per the CSR Policy of the Company.
- C. The Grant Holder is a leading centre of research in India on mathematics and theoretical physics, located in Allahabad. The Grant Holder is seeking funds for instituting a chair-professorship. The request is for a corpus grant of Rs 5,00,00,000 (Rupees Five Crores only) to support a chair in the area of mathematics or theoretical physics.

Bangaloro

J.K. Pohatt charge

Page 1 of 8

D. The Parties are now desirous of executing this binding MOU setting out the terms and conditions for the Grant and to record their mutual rights and obligations in relation to the operation, administration and management of the Grant and the Project.

NOW THEREFORE the Parties set forth their understanding as follows:

1. Funding, Use and Release of Grant

a. Partial Funding

If a Project is conditional upon the receipt of funding from other sources then the Grant shall not commence until such funding from other sources has been received or successful confirmation has been given in writing to the Grant Holder.

b. Use of Grant

- (i) The Grant must be exclusively used for the scope of activities / proposed Project mentioned in the Grant Application Form in compliance with all laws. A copy of the filled Grant Application Form is enclosed herewith as **Annexure A**. Use of Grant for any other purposes, without the prior written approval of Foundation, would amount to a material breach of this MOU and Foundation may terminate the Grant immediately.
- (ii) Grant Holder shall ensure that the Grant is used within the time period specified in the Grant Application Form. The Grant Holder must specify the reasons in writing for delay in the start date (as specified in the Grant Application Form) of the Project. Foundation will not be responsible for any escalation in cost of the project due to the delay in the start or completion of the Project by the Grant Holder.

c. Release of Grant

Grant Holder shall submit to the Foundation a report in the format specified in **Annexure B** in March every year. Foundation may request for additional report. Grant Holder will also submit a certificate of compliance with all applicable laws. Foundation will not release any additional tranches of the Grant if Grant Holder fails to submit the annual report.

2. Monitor and review of Grants

a. Reports

(i) **Progress Report:** If not submitted under Clause 1 (c) above, then Grant Holders must provide a report at such interval as may be required by Foundation in the format specified in **Annexure B**.

Rangalore

J. K. Bhatt chayer

Page 2 of 8

- (ii) Completion Report: Grant Holder must submit to Foundation a final written completion report, which describes all stages of the Project in sufficient details within 45 days of the completion of the Project.
- (iii) The Grant Holder may include any additional information it deems fit in the Progress Report and/or Completion Report. Foundation may request additional information. Failure to submit either the Progress Report and/or Completion Report (as the case may be) may result in termination of grant or debarment from any future grants.

b. Site Visits and Milestones

- (i) The representatives of Foundation or the Company may make visits to the project site by giving reasonable notice to the Grant Holder.
- (ii) The Parties have agreed to the milestones and indicative timelines hereto with the respect to the Project.

Project Term:

- i. The estimated start date of the project is August 1, 2018
- ii. The corpus fund will last for a period of 25 years. The interest from the corpus must be completely used on an annual basis.
- iii. The corpus fund must mandatorily be kept as a fixed deposit in a nationalized bank or private bank consistently top ranked in the market for the last 5 years.
- iv. The corpus fund will be named 'The Infosys Endowment Fund for Mathematics or Theoretical Physics'.
- v. The chair will be named 'The Infosys Chair Professorship'.

Project Details:

- The professor shall be an internationally distinguished scientist in mathematics or theoretical physics and identify himself or herself as Infosys Chair Professor.
- ii. The annual interest must be towards the activities of the Infosys Chair Professor such as providing remuneration, travel costs, and hardware and software requirements.
- iii. The program must encourage
 - o High quality research
 - Inspirational teaching
 - o Visibility for Harish Chandra Research Institute
- The Grant Holder shall display 'Supported by Infosys Foundation' at the campus premises, in all publications (either in the text or the footnote) on its website, published papers, articles, interviews, lectures, research and relevant



J. K. PShattecharge

Page 3 of 8

material, event programs, marketing material and in other places for efforts that are supported through the corpus.

(iii) The Foundation or the company reserves the right to come up with additional milestones as and when it deems fit and that such milestones shall be deemed to have been incorporated herein.

c. Audit & Board of Advisors report

The Grant Holder will submit receipts and payments statement (certified by the trustees of the Grant Holder) of the Project by March 8 every year. Such statement must contain details of the receipts and payments for the entire year and sum total expenditure till the date of the statement.

3. Suspension or Termination of the Grant

- a. This MOU shall come into effect on execution and shall be in full force until the earlier of:
 - (i) the mutual written termination of this MOU.
 - (ii) acceptance of the completion report by Foundation.
- b. Notwithstanding anything else in this MOU and without prejudice to any other rights that Foundation has under law and/or this MOU, Foundation may suspend or terminate the Grant:
 - (i) Immediately with notice in case of a material breach of this MOU, provided that Foundation may in its discretion give the Grant Holder an option to remedy the breach.
 - (ii) Immediately with notice if the Grant Holder's or its representatives' (includes employees, volunteers, agents, vendors etc.) acts or omission, in Foundation opinion, bring disrepute to Foundation or the Company.
 - (iii) By giving 30 days' notice for any reason whatsoever.

4. Representations & Warranties

As on the date of this MOU and on the funding of each tranche, the Grant Holder represents and warrants that:

- (a) it is duly incorporated, validly existing and in good standing under the laws of the state or country in which it was incorporated
- (b) it has all necessary corporate power and authority to enter into MOU and carry out the CSR activity for which the Grant is being given.
- (c) Receipt of the Grant does not violate any laws, rules, policies, guidelines applicable to the Grant Holder or Foundation or the Company.

* Sangalote

V. K. Bhattahayee

Page 4 of 8

5. Professional Ethics; Compliance with Laws.

- (a) Grant Holder must comply (and will ensure its officers, trustees, directors, employees and contractors, agents and any person or entity acting on its behalf or under its control comply) with all applicable national and international laws (including anti-corruption Laws like the U.S. Foreign Corrupt Practices Act, laws relating to the employment of its employees, employee tax withholding applicable to its employees or environmental and health and safety laws relating to its employees or facilities). No payments or transfers of value which intend to or effect public or commercial bribery, acceptance or acquiescence in extortion, kickbacks or other unlawful or improper means of obtaining or retaining business or directing business to any person or entity, and no facilitation payments will be made.
- (b) Grant Holder will not pay any salaries, commissions, fees or make any payments or rebates to any employee or agent of Foundation or the Company, or to any designee of such employee or agent, or favor any employee or agent of Foundation or the Company, or any designee of such employee or agent, or otherwise provide any gifts, entertainment, services or goods to such employees or agents in violation of this MOU.
- (c) Grant Holder shall not use any form of slave, forced, bonded, indentured, or involuntary prison labor. They shall not engage in human trafficking or exploitation, or import goods tainted by slavery or human trafficking. They shall not retain employees' government-issued identification, passports or work permits as a condition of employment. Further, Grant Holder shall ensure that no underage labor (as determined by the local law) has been used in the production or distribution of goods or services.
- (d) Grant Holder shall promote and maintain a workplace free from discrimination and treat its employees with fairness, dignity and respect. No form of physical, sexual, psychological or verbal harassment or abuse shall be tolerated.
- (e) No animals, birds shall be harmed, tortured or cruelly treated in the performance of the Project.

Breach of any of the aforementioned conditions will lead to immediate termination of the Grant.

6. Indemnity, Limitation of Liability

(a) The Grant Holder agrees to indemnify Foundation, the Company, its directors, trustees, officers, employees, successors and assigns from and against all claims, damages, liabilities, losses and costs including reasonable attorney's fees in connection with or relating to, any claims or proceedings to the extent arising from:

& Bangalore

J. K. PS hattedaye

Page 5 of 8

- (i) Grant Holders negligence or intentional acts or omissions
- (ii) Grant Holders breach of this MOU, Grant Application Form or any other document which imposes the terms and conditions of the Grant on the Grant Holder.
- (b) Foundation will, under no circumstance, be liable for or indemnify any institutions, Grant Holder or its director, officers, personnel's for any costs, expenses, liability or claims arising from the termination or suspension of the Grant including but not related to any liability arising from employees related matters of the Grant Holder.
- (c) Foundation will not be responsible, financially or otherwise, for any expenditures or liabilities arising out of the Project. Notwithstanding anything else in this MOU, Foundation shall not be liable to the Grant Holder, any institutions or any other person for any amount in excess of the Grant.
- (d) Neither party shall be liable for any indirect, special, incidental, consequential, or punitive damages, however caused, including, without limitation, any damages resulting from or arising out of or in connection with this Condition of Grant, or of any other obligations relating to this MOU, whether or not it has been advised of the possibility of such damages.

7. Publication

- (a) Wherever applicable, the findings from the project funded by the Grant should be made freely available to the community as soon as possible.
- (b) Grant Holders must take prior approval of the Foundation office before any results related to the Project are published or presented.
- (c) Grant Holder will prominently display 'Supported by Infosys Foundation' in all publications (either in the text or the footnote) on its website, event program, marketing material and in other places.
- (d) Foundation may use any information, data or other material from the project funded by the Grant as part of its fundraising or publicity activities.

8. Governing Law & Jurisdiction

This MOU, the Grant shall be construed according to the law of the Republic of India. The Grant Holder irrevocably submits to the exclusive jurisdiction of the courts in Bangalore for all matters related or ancillary to this MOU and/or the Grant.

9. Additional Conditions; Amendment

(a) The aforementioned are the general terms and conditions of the Grant. Foundation reserves the right to impose additional conditions and shall inform the Grant Holder of such conditions. Such conditions shall apply from the date that such additional conditions are communicated to the Grant Holders.

Page 6 of 8



- The Foundation may assign any of the rights (but not the obligations) to the (b) Company with written notice to the Grant Holder. The Grant Holder cannot assign any of its rights or obligations without the prior written approval of the Foundation. Any attempt to do so shall be null and void.
- This MOU constitutes and contains the terms of agreement between the Parties. (c) No amendment of this MOU will be effective unless it is in writing and signed by both the Parties.

IN WITNESS WHEREOF, the Parties have executed this MOU as of the date first written above.

BY INFOSYS FOUNDATION

Through its authorised signatory

Name: Sudha Murty

Designation: Chairperson

Sudha Murty

Witness:

Address: Neralu, 1/2 (1878), 11th Main, 39th Cross,4th T Block, Jayanagar, Bangalore-560011

BY HARISH CHANDRA RESEARCH INSTITUTE

Through its authorised signatory

J. K. Pohotte dage.

Name: Jayanta Bhattacharje Director Designation: Directosh-Chandra Research Institute Chhatnag Road, Jhunsi Allahabad-211019

Witness: Seema

Agarwal.

Address: Harish Chanelra Research Institute Chhatney Road Thunsi. Allahabad. - 211019

J. K. Pohattahayer

Annexure A

Filled Grant Application Form to be enclosed

Annexure B

Project Report to be enclosed



24079 ਜਵਰ 18726 कर्नाटक NOV 29 2017

zen zen zen zen Privilleged and Confidential
INDIARS 0000200 PB7140

STAMP DUTY

KARNATAKA

TERMS OF THE GRANT HARISH CHANDRA RESEARCH INSTITUTE

The following are the general terms of the Grant made at Bangalore on 29 date of November 2017 and are binding and applicable to the Grant awarded to you. The Grant must be used in accordance with the terms herein. Any breach of the following terms may lead to immediate suspension or termination of the Grant.

- Grant Holder: Harish Chandra Research Institute having PAN AAAAH0499K and its office at Chhatnag Road, Allahabad, Uttar Pradesh – 211 019, India.
- Infosys Foundation ("Foundation") and Grant Holder are referred to individually as "Party" and collectively as "Parties".
- Project Description: The donation is towards the establishment of two professorships.
 This includes the invitation of eminent senior professors as Infosys Distinguished Visiting
 Professors and younger outstanding faculty as Infosys Visiting Professors to the Harish
 Chandra Research Institute in Allahabad.
- 4. Grant Amount: Rs. 40,00,000 (Rupees Forty Lakhs Only) ("Grant").
- 5. The Grant must be used for the scope of activities / proposed Project mentioned in the Grant Application Form in compliance with all laws, and the activities supported by the Grant must be completed within one year of the Grant Date. A copy of the filled Grant Application Form is enclosed herewith as Annexure A.
- 6. Grant Holder shall ensure that the Grant is used within the time period specified in the Grant Application Form. The Grant Holder must specify the reasons in writing for delay in the start date (as specified in the Grant Application Form) of the Project. Foundation will not be responsible for any escalation in cost of the Project due to the delay in the start or completion of the Project by the Grant Holder.
- Grant Holder shall submit to the Foundation a final written completion report, which
 describes all stages of the Project in sufficient details within 45 days of the completion of
 the Project. Foundation may request for additional information/reports.
- Foundation may make visits to the Project site by giving reasonable notice to the Grant Holder.
- These terms herein shall come into effect on release of the Grant and shall be in full force until the earlier of (a) termination of these terms by the Foundation, or (b) acceptance of the completion report by Foundation.
- 10. Notwithstanding anything else herein, Foundation may suspend or terminate the Grant (a) Immediately with notice if the Grant Holder's or its representatives' acts or omission, in Foundation opinion, bring disrepute to Foundation or Infosys Limited ("Company"), or (b) by giving 30 days' notice for any reason whatsoever

* Gangalore

Print

Page 1 of 3

- 11. Grant Holder must comply (and will ensure its officers, trustees, directors, employees and contractors, agents and any person or entity acting on its behalf or under its control comply) with all applicable national and international laws.
- 12. Grant Holder will not pay any salaries, commissions, fees or make any payments or rebates to any employee or agent of Foundation or the Company.
- 13. Grant Holder shall not use any form of slave, forced, bonded, indentured, or involuntary prison labor. They shall not engage in human trafficking or exploitation, or import goods tainted by slavery or human trafficking.
- 14. Grant Holder shall promote and maintain a workplace free from discrimination and treat its employees with fairness, dignity and respect. No form of physical, sexual, psychological or verbal harassment or abuse shall be tolerated.
- 15. No animals, birds shall be harmed, tortured or cruelly treated in the performance of the Project.
- 16. Notwithstanding anything else herein, Foundation shall not be liable to the Grant Holder, any third party for any amount in excess of the Grant.
- 17. Neither party shall be liable for any indirect, special, incidental, consequential, or punitive damages, however caused, including, without limitation, any damages resulting from or arising out of or in connection with these terms.
- 18. The findings from the Project funded by the Grant should be made freely available to the community as soon as possible.
- Grant Holder must take prior approval of the Foundation before any results related to the Project are published or presented.
- 20. Grant Holder will name the professorships as described above in Project Description clause. Further, the Grant Holder will prominently and permanently address the professorships as Infosys Distinguished Visiting Professors and younger outstanding faculty as Infosys Visiting Professors in the premises of the Institute, publications (either in the text or the footnote) including its website, programs, marketing material, and in other places, as appropriate.
- 21. Foundation may use any information, data or other material from the project funded by the Grant as part of its fundraising or publicity activities.
- 22. These terms and the Grant shall be construed according to the law of the Republic of India. The Grant Holder irrevocably submits to the exclusive jurisdiction of the courts in Bangalore for all matters related or ancillary to Terms of Grant.
- 23. Foundation reserves the right to impose additional conditions and shall inform the Grant Holder of such conditions. Such conditions shall apply from the date that such additional conditions are communicated to the Grant Holders.
- 24. The Foundation may assign any of the rights (but not the obligations) to the Company with written notice to the Grant Holder. The Grant Holder cannot assign any of its rights or obligations without the prior written approval of the Foundation. Any attempt to do so shall be null and void.

Bangalore

Print print

Page 2 of 3

BY INFOSYS FOUNDATION

BY HARISH CHANDRA RESEARCH INSTITUTE

Through its authorised signatory

Radio Hunday

Name: Sudha Murty

Designation: Chairperson

Lewy &

Witness: Shrutkeerti Khurara

Address: Neralu, #1/2 (1878), 11th Main, 39th Cross, 4th T Block, Jayanagar,

Bangalore - 560 011

Through its authorised signatory

Name: PINMU

MD Pirector

Designation:

Chhatrag Road, Jhun TO Allahabad 211019

Vitness: ANIRBAN BAN

Address:

TRI

GOVERNMENT OF INDIA MINISTRY FOR SCIENCE & TECHNOLOGY DEPARTMENT OF BIOTECHNOLOGY

RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY THIRUVANANTHAPURAM 695014 An Autonomous National Institute for Discovery, Innovation & Translation in Biotechnology and Disease Biology

6242-P61/RGCB/PMD/DBT/ARMR/2015

July 30, 2018

RELEASE ORDER

In Continuation of this Department's sanction order of even number dated July 29,2015, sanction of the resident is hereby accorded, under Rule 18 of the Delegation of Financial Powers Rule,1978,for the release of Rs. 4,04,500 (Rupees Four Lakhs Four Thousand Five Hundred Only) being the final year release for the project "Targeting the life-threatening complications (HVOD & GVHD) associated with allogeneic Haematopoietic Stem Cell Transplantation (allo HSCT)",being implemented Dr. Vikram Gota, Department of Clinical Pharmacology, Advanced Centre for Treatment Research & Education in Cancer (ACTREC), Tata Memorial Centre (TMC), Kharghar, Navi-Mumbai-410 210.

2. The amount of **Rs. 4,04,500 (Rupees Four Lakhs Four Thousand Five Hundred Only)** will be drawn by the Drawing & Disbursing Officer, Rajiv Gandhi Center for Biotechnology (RGCB), from DBT and

disbursed through RTGS/Demand Draft as per following details:

Tata Memorial Centre (TMC), Advanced Centre for Treatment Research & Education in Cancer (ACTREC)

Bank Name

: Central Bank of India

Branch Name

: Kharghar, Navi-Mumbai

A/c No. IFSC Code : 1797305746 : CBIN0284047

- 3. Advanced Centre for Treatment Research & Education in Cancer (ACTREC), will submit audited Utilization Certificates and statements of expenditure in respect of the above-mentioned amount.
- The Accounts of grantee institution shall be open to inspection by the sanctioning authority/audit When ever the Institute is called upon to do so by the sanctioning authority.
- 5. No International Travel will be undertaken from the sanctioned project grant unless specified otherwise
- 6. (a) In case the whole or a part of the amount of grant-in-aid is being refunded, an interest at the rate of ten Percent annum thereon shall be recovered.(b) Non-Recurring grant shall be utilized within 18 months of their release. The other terms and conditions governing the financial sanction will remain unaltered
- This issues under powers delegated to the Rajiv Gandhi Centre for Biotechnology, vide letter No.DO.No.BT/Med/Pilot Project Cancer/2014 dated 26.06.2015 and Department of Biotechnology with the concurrence of IFD, DBT.

8. This Sanction order has been noted at serial no. 61 in the Register of Grants.

Chief Project Officer

Pilot Project Grants, Program for Young

Investigators in Cancer Biology

Raijy Gandhi Centre for Biotechnology

To,

The Finance Officer, Rajiv Gandhi Centre for Biotechnology (RGCB) Thycaud P.O,Poojappura, Thiruvananthapuram-695014

Copy to:

- 1. The Principal Director of Audit, (Scientific Departments), AGCR Building, New Delhi 110002.
- 2. The Principal, Advanced Centre for Treatment Research & Education in cancer, Navi, Mumbai-410210
- 3. Dr. Anuradha Majumdar, PI, Bombay College of Pharmacy, Kalina Mumbai-400098
- Dr. Vikram Gota,PI,,Advanced Centre for Treatment Research & Education in cancer,Navi,Mumbai-410210
- 5. Dr.Navin Khattry, (CI), Advanced Centre for Treatment Research & Education in cancer, Navi, Mumbai-410210
- 6. Dr.P.R.Chaudhari,(CI) Advanced Centre for Treatment Research & Education in cancer, Navi, Mumbai-
- 7. Mr.Anand.G.Patil, (CI)Advanced Centre for Treatment Research & Education in cancer, Navi, Mumbai-410210
- 8. Cash Section, RGCB (2 Copies).
- 9. Sanction Folder.
- 10. File Copy.

D.72) 1962 10/7/18



FORM - J CLAIM BILL FORM

25/02/25/2 COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH

Human Resource Development Group CSIR Complex, Library Avenue, Pusa, New Delhi - 110012

(To be photocopied, filled and submitted in triplicate)

To .	• .
HEAD (HRDG)	
Council of Scientific & Industrial Research CSIR COMPLEX, LIBRARY AVENUE (OPP. IN	ST OF HOTEL MANAGEMENT), PUSA, NEW DELHI 110 012.
Bill No.	
CSIR Sanction No. 27(0314)/16/EMR-II Date	ed 24.04.2018
Name of Scheme in full: Identification (of potential regulators associated with modulation in
IGI-1R signaling in chemoresistant ovar	rian cancer cells
	<u> </u>

PARTICULARS ;			AMO	UNT OF	GRANT		REMARKS
	Staff	Cont.	Eqpt.	HRA*	Overhead Exp.	TOTAL	
L Amount Sanctioned for Year	NA	4,00,000	NA	NA	NA	4,00,000	,
2. Amount Claimed for period from	NA	4,00,000	NA	NA	NA	4,00,000	
01/04/2018 to 31/03/2019							
Deduct:							
3. Unspent balance from the grant of last year		38,080	NA	NA	NA		
4. Net amount claimed		361,920	NA	NA	NA	361,920	

- 1) Certified that the amount claimed in this bill will be utilised for the purpose for which it has been sanctioned and the audited statement of expenditure will be furnished as per requirement. We agree and abide by the Terms and Conditions that the excess expenditure, if any, incurred will be met from institution's funds and not from CSIR funds.
- 2) Certified that the persons for whom HFA has been claimed have not been provided any accommodation and HRA claim is as per rules of this Institute. (Details of the staff for which grant under "Staff" is claimed should invariably be given on the reverse). The rate of H.R.A. may be indicated against the name of Fellow for whom H.R.A. has been claimed. .

Counter-Signature & Des Head of the Institution w Office Stamp	STR Dr. S. V. Chiplunkar ignational Centre for Treatment, Research & Education in Cancer (ACTREC) Tata Memorial Centre Kharghar, Navi Mumbal-410210.	Prilta Roy 25/5/18 Signature of the Principal Investigator
	(This space is to be filled in by the CSIR)	· ·
Gr No Pay Rupees 361920	dated 6/7/2018 1- CPo. Three herkho Sinty be + heity only	ore. Howard nine fundor
Issued in favour of	A.C.T. R.E.C. Tota Memorial Ce Khangher	Section Officer
For use of Audit:		
Budget Head		
Mish-EG	dated	
Pay Rs.		
Rupees		only.
on Thered be	et Signicling Itio Lab. Ite. Memorial Havi Mumbai-410210	Page 2 of 3

GOVERNMENT OF INDIA MINISTRY FOR SCIENCE & TECHNOLOGY **DEPARTMENT OF BIOTECHNOLOGY**

RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY THIRUVANANTHAPURAM 695014 An Autonomous National Institute for Discovery, Innovation & Translation in Biotechnology and Disease Biology

6242-P66/RGCB/PMD/DBT/ARVM/2015

July 29th 2015

ORDER

- In continuation to letter Number: DO.No.BT/Med/Pilot Project Cancer/2014 dated June 26th 1. 2015, Rajiv Gandhi Centre for Biotechnology (RGCB) will function as the Project Management Group for the PILOT PROJECT GRANT FOR YOUNG INVESTIGATORS IN CANCER BIOLOGY being funded by the Department of Biotechnology, Government of India
- 2. Sanction is hereby accorded on instructions from the Department of Biotechnology, Government of India for the implementation of the project entitled: " Understanding the mechanisms of ALA-induced fluorescence in malignant gliomas - Exploring the biological basis of tumoral heterogeneity.",under PILOT PROJECT GRANT FOR YOUNG INVESTIGATORS IN CANCER BIOLOGY at a total cost of Rs. 24,96,000/- (Rupees Twenty Four Lakhs Ninety Six Thousand Only) on the terms & conditions explained in Office Memorandum No: BT/2/2015-IFD dated14th July, 2015 from the Department of Biotechnology, Government of India and the following conditions detailed below.
- Title of the Project: : " UNDERSTANDING THE MECHANISMS OF ALA-INDUCED 3. FLUORESCENCE IN MALIGNANT GLIOMAS - EXPLORING THE BIOLOGICAL BASIS OF TUMORAL HETEROGENEITY
- **DETAILS OF INVESTIGATOR (S)** 4.

PRINCIPAL INVESTIGATOR: DR ALIASGAR V MOIYADI

(aliasgar.moiyadi@gmail.com)

Dept of Neurosurgery, ACTREC, Tata Memorial Centre, PS 245, Kharghar, Navi

Mumbai - 410210

TEL-: 022 27405076, FAX-022 27405061

CO-INVESTIGATOR I: DR EPARI SRIDHAR.. (sridhep@gmail.com)

Dept of Pathology, ACTREC, Tata Memorial Centre, PS 245, Kharghar, Navi Mumbai -

410210

TEL-: 022 27405000, FAX-022 27405061

CO-INVESTIGATOR II: DR VIKRAM GOTA. (vgota@actrec.gov.in)

Dept of Translational Pharmacology ACTREC, Tata Memorial Centre, PS 245,

Kharghar, Navi

Mumbai -410210

TEL-: 022 27405130, FAX-022 27405061

CO-INVESTIGATOR III: DR SANJEEVA SRIVASTAV. (sanjeeva@iitb.ac.in)
Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay,
Powai,Mumbai 400 076, India
TEL-:22-25767779

5. Objectives

- To assess the differential fluorescence within tumors of the similar grade
- To correlate the accuracy of the fluorescence technique with existing non invasive imaging techniques (MRI and PET)
- **5. Time Schedule:** The duration of the project is 3 years (36 months) from the date of the sanction order.

6. Project Cost

The total approved cost of the project is Rs. 24, 96,000/- (Rupees Twenty Four Lakhs Ninety Six Thousand Only)

Budget Head	Year 1	Year II	Year III	Total(Rs)
Equipment	Nil	Nil	Nil	Nil
Manpower	1,80,000	1,80,000	Nil	3,60,000
×	9,66,000	10,90,000	Nil	20,56,000
Consumables	2	, m		:00:
Travel	Nil	25,000	25,000	50,000
Contingency	10,000	10,000	10,000	30,000
Overhead	Nil	Nil	Nil	Nil
Total(Rs)	11,56,000	13,05,000	35,000	24,96,000

- 8. Equipment: Details of equipment sanctioned for implementation of the project is given in Annexure I.
- Man Power: Details of manpower sanctioned for implementation of the project is given in Annexure II

10. Head of Account:

The Non-Recurring and Recurring expenditure involved is debitable to **RGCB Pilot Project Account.**

11. Terms and Conditions:

- i. A duly constituted committee will monitor progress of work, once in a year, considering the time bound nature of the sanctioned project.
- ii. The date of release of grants is the date of the Sanction Order.
- iii. Any extension proposal should be submitted before 6 months from the probable date of completion of the project.
- iv. It is the responsibility of the PI and Institute to ensure that support of the Department of Biotechnology is suitably acknowledged in any publication, patent, reports, etc arising out of the project.
- v. As per GFR, equipment sanctioned under the project should be purchased within 18 months from the date of sanction order.
- vi. The Grantee Institute is permitted to carry forward the unspent balance for the previous financial year after furnishing UC/SE in the Department of Biotechnology, Government of India format to Rajiv Gandhi Centre for Biotechnology (RGCB) for the previous financial year ending.
- vii. In case, the whole or a part of amount of the Grant-in-aid is being refunded, an interest at the rate of 10% annum there on shall be recovered.
- 12. Other terms and conditions governing this sanction are attached at Annexure-III.
- 13. The Memorandum of Agreement (MOA) will be signed between Rajiv Gandhi Centre for Biotechnology (RGCB) and the Grantee Institution on Judicial Stamp Paper of Rs: 100/- in the enclosed format. The first release of grant will be made only after signing of this MOA by the grantee institution. A format of the MOA is enclosed in **Annexure IV**.
- 14. The grantee institute will keep the whole of the grant in a bank account earning interest. The interest so earned should be reported to RGCB in the Utilization Certificate and Statement of Expenditure. The interest so earned will be treated as created to the institute and shall be adjusted towards further installment of the grants and or at the time of final settlement of accounts.
- 15. No International travel will be undertaken from the sanctioned project grant.
- 16. <u>Dr Rajiv Sarin, Director, ACTREC, Kharghar, Navi Mumbai</u> would be responsible for submission of Statements of Expenditure (S/E) and Consolidated Utilization Certificates (U/Cs) to RGCB from PI's in respect of Grants release against this sanction order from time to time.
- 17. The accounts of grantee institution shall be open to inspection by the sanctioning authority/audit whenever the institute is called upon to do so accordingly.
- 18. This issues under powers delegated to the Rajiv Gandhi Centre for Biotechnology, vide letter No.DO.No.BT/Med/Pilot Project Cancer/2014 dated 26.06.2015 and Department of Biotechnology with the concurrence of IFD, DBT.
- 19. This sanction order has been noted at serial No. 66 in the Register of Grants.

Chief Project Officer

Pilot Project Grants, Program for

Young Investigators in Cancer Biology

Rajiv Gandhi Centre forBiotechnology

To,

The Finance Officer, Rajiv Gandhi Centre for Biotechnology (RGCB), Thycaud P.O, Poojappura, Thiruvananthapuram -695014.

Copy to:

- 1. The Principal Director of Audit, (Scientific Departments), AGCR Building, New Delhi 110002
- 2. Director, ACTREC, Kharghar, Navi Mumbai
- 3. Dr Aliasgar V Moiyadi, Pi, Actrec, Tata Memorial Centre, PS 245, Kharghar, Navi Mumbai 410210
- 4. Dr Epari Sridhar(,CI-1), ACTREC, Tata Memorial Centre, PS 245, Kharghar, Navi Mumbai 410210
- 5. Dr Vikram Gota(,CI-2),ACTREC, Tata Memorial Centre, PS 245, Kharghar, Navi Mumbai 410210
- Dr Sanjeeva Srivastav,(Cl-3), Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai, Mumbai 400 076, India
- 7. Cash Section, RGCB (2 Copies).
- 8. Sanction Folder.
- 9. File Copy.













To,

Date: 04/10/2017

FCIPT, Institute of Plasma Research A-10/B, G.I.D.C., Sector-25, Gandhinagar-382 016, Gujarat, India.

Kind Attention: Dr. Nirav Jamnapara

Subject: Processing of Nano Zinc oxide powder from our material

Ref: Your proposal no. FCIPT/ENQ/17-18/28 dated 29-09-2017

Dear Sir,

We thank you for your valued support for processing of Zinc nano oxide powder at IPR and hereby place work order for the same as below.

Sr. no.	Description	Quantity	Rate (INR)	Remark
1.)	Zinc Oxide nano powder	10 kgs		Package includes characterization of nano powders (SEM,XRD,TEM)- on 2 sperate batches as required over a period of 6 months.

Terms & Conditions

- 1. Price basis:
 - a. Price is exclusive of any taxes or duties.
 - b. GST or other taxes as applicable will be extra at prevailing Govt. norms.
- 2. <u>Payment terms:</u> 100% as advance payment along with confirmed Order in favour of INSTITUTE FOR PLASMA RESEARCH (A/c FCIPT), Gandhinagar.
- 3. Validity of proposal: 60 days from date of proposal.
- 4. Tenure: 06 months from the date of receipt of advance payment.
- 5. <u>Intellectual Property (IP):</u> All the background intellectual property held by both the organizations will be held confidential respectively by each other.
- 6. Force Majeure: FCIPT-IPR will not be responsible for any delay in executing the above proposed activity due to any reasons beyond its scope of control such as war, epidemics, natural disasters, labor problems/strike at our our supplier's works, acts of GOD, or delay due to attaining test results of processed material, or any activity of other party linked with FCIPT's scope etc.

Page 1 of 2

CIN No.: U28112GJ2011PTC064857













7. Liability: FCIPT-IPR shall not be liable for any failures whether financial, technical or whatsoever, arising out of this agreement. VEGPL has been made aware and accepts that the scope of work under this agreement is purely demonstration purpose and FCIPT-IPR will not be responsible for any loss arising due to use of such products. VEGPL shall not hold FCIPT-IPR liable for any damages, demands, expenses or losses asserted by VEGPL or third party out of this agreement.

8. Jurisdiction: Any and all disputes arising out of this contract shall be subject to Gandhinagar_Jurisdiction only.

Company Details :-

Invoice Name: Vishal Engineers & Galvanizers Pvt. Ltd.

Address

: 73, Ashwamegh Indust. Estate

Sarkhej-Bavla N.H.8-A, Changodar-382213 GST NO.: 24AADCV6091Q1ZO

Tal. Sanand, Dist: Ahmedabad State: GUJARAT, Code: 24

Phone No.

: 02717 250 255

Contact Person: Mr. Vikalp P. Joisar - 9377222200

TIN. NO. 24074501719 Dt.2-10-04

CST No. 24574501719 Dt.28-10-04

PAN No. AADCV 6091 Q

ECC No. AADCV 6091 Q EM001

Ex. Range: AR III

Division: IV Changodar

Collectorate: Ahmedabad-II

For,

Vishal Engineers & Galvanizers Pvt. Ltd.

For,

Institute of Plasma Research

JOISAR

Page 2 of 2

CIN No.: U28112GJ2011PTC064857

INVOICE

Invoice No		Dated	ı			
Delivery No	ote	Mode	/Term	s of Payment		
Supplier's	Ref.	Other	Refer	rence(s)		
E-mail Dt	d 11.10.17					
		Dated				
Despatch [Document No	. Delive	ery No	te Date		
Despatche	d through	Destir	nation			
Terms of Delivery						
HSN/SAC	Quantity	Rate	per	Amount		
				7		
	1.00 NOS	81,000.00	NOS	81,000.00		
t)		9	%	7,290.00		
		9	%	7,290.00		
		×				
al	1.00 NOS			₹ 95,580.00		
	,			E. & O.E		
				*		
		for Institu	te for	Plasma Research		
	8		F. Ai	.5hah uthorised Signatory		
	SI/043/17 Delivery No Supplier's E-mail Dt Buyer's On Despatch I Despatche Terms of D	SI/043/17-18 Delivery Note Supplier's Ref. E-mail Dtd 11.10.17 Buyer's Order No. Despatch Document No Despatched through Terms of Delivery HSN/SAC Quantity 1.00 NOS	SI/043/17-18 Delivery Note Mode Supplier's Ref. E-mail Dtd 11.10.17 Buyer's Order No. Despatch Document No. Despatched through Terms of Delivery HSN/SAC Quantity Rate 1.00 NOS 81,000.00 1) 9 9	SI/043/17-18 Delivery Note Delivery Note Supplier's Ref. E-mail Dtd 11.10.17 Buyer's Order No. Despatch Document No. Despatched through Terms of Delivery 1.00 NOS 1,000.00 1.00 NOS 1,000.00 1,0		

This is a Computer Generated Invoice

एफ. ए. शाह F. A. Shah लेखा अधिकारी-I Accounts Officer-I पाला बनुसंबन संस्थान Institute For Plasma Research

Facilitation Centre for Industrial Plasma Technologies INSTITUTE FOR PLASMA RESEARCH

(An Autonomous Institute of Department of Atomic Energy, Government of India) A-10/B, G.I.D.C., Sector-25, Gandhinagar-382 016, Gujarat, India

FCIPT/Offer/037/16-17 Date- 29th March 2017

Plasma Research

Phone: +91-79-23269026, 23269017

Fax : +91-79-23269001 E-mail : <u>avisani@ipr.res.in</u>

To,

ABREF PVT LTD F17, Sipcot, Gummidipoondi, Tamilnadu - 601 201 India www.abref.in

Email: info@abref.in,vijayraj.abref@gmail.com

Sub: Offer for Feasibility studies on Interaction of Thermal Plasma with Fly Ash

Dear Sir,

This is in reference to your email dated-13.02.2017 and our meeting at FCIPT on 01.03.2017 with your requirement to conduct feasibility study on interaction of thermal plasma with Fly Ash.

We have worked out a feasibility study proposal based on our expertise and available background information to fulfill your requirement.

As per the proposal, we will conduct experiments on interaction of thermal plasma with Fly Ash to investigate the possible production of SiAlON. A detailed project report with results will be submitted to M/s ABREF Pvt. Limited after completion of the project. Once the study is completed successfully and if positive results are obtained, we shall work out for scaling up the process as per requirement.

Hope the attached proposal is in line with your requirement. Please feel free to call us for any further information that you may require.

Thanking you and looking forward to a fruitful collaboration ahead.

With best regards,

Anand Visani T. C. Cell



PROPOSAL:

This proposal is for feasibility study on interaction of thermal plasma with Fly Ash. A dc non-transferred nitrogen thermal plasma torch will be developed and fly ash will be introduced into the thermal plasma plume. The treated product will be collected downstream and investigated for the possible production of SiAION.

METHODOLOGY OF EXECUTION:

Execution of this proposed work will be done in following steps:

- A 10 KW- 25 KW dc plasma torch will be fabricated using carbon (graphite) electrodes and installed on a chamber that will be initially evacuated to vacuum ~10 mbar. Nitrogen will then be flushed to maintain atmospheric pressure.
- Appropriate arrangement/provision will be done to inject the cold gas and/or fly ash into the plasma plume.
- Studies will be conducted at different power levels (up to 25 kW) and flow of plasma generating gas and rate of fly ash introduction.
- Treated sample will be collected downstream and tested for presence of SiAlON.
- The same experiment will be tried by taking a mixture of alumina, silica and carbon in a carbon crucible and treated by transferred arc plasma method.
- Powders obtained from both the above methods will be characterized by XRD for the possible presence of SiAION.
- In the event of the presence of SiAlON, phase identification will be checked by XRD and shape and size of grains by SEM.
- A report will be submitted to M/s ABREF Pvt. Ltd. containing details of the studies conducted and results obtained.

SCOPE OF WORK:

The scope of work is described below:

FCIPT's scope of work:

- Studies on the interaction of Fly ash with Nitrogen Thermal Plasma.
- Collection of treated powder and explore the presence of SiAlON.
- ❖ Testing of the collected powder using XRD and SEM for phase identification and shape and size of grains respectively.
- Preparation and submission of project report.
- Optimization of conversion efficiency of Fly Ash or Alumina+Silica+Carbon powder mixture to SiAION is NOT in the scope of this feasibility study.

ABREF's scope of work:

- Supply of Fly Ash, and good quality Alumina, Silica and Carbon powders.
- Any other activity, that is required for the proposed project but is not under FCIPT's scope of work.

DELIVERABLES:

Technical report which includes experiment procedure followed in the study and results of the experiments.

TIME SCALES:

The time required for conducting the proposed experiments shall be 6 months from the date of receipt of advance.

COST:

The charges for activities under FCIPT scope of work are as given below:

Sr. No.	Activity	Amount in Rs.
01	Charges for Feasibility study (including, experiments charges, analysis charges, manpower, overheads and consumables & contingencies charges)	3,00,000/-
	TOTAL OF ABOVE Rupees Three Lakhs only	3,00,000/-

TERMS & CONDITIONS:

1. Payment terms:

- a. 80% as advance payment along with P.O. / Agreement
- b. 20% against Submission of final technical report.
- c. All payments to be made in favor of **INSTITUTE FOR PLASMA RESEARCH (A/c FCIPT)**, Gandhinagar.
- 2. Validity of quote: 30 days from date of offer/proposal
- **3. Tenure:** 6 months from the date of receipt of advance payment.

4. Intellectual Property (IP):

All the background intellectual property held by both the organizations will be held confidential respectively by each other. Any intellectual property relating to plasma processing system and processing, as generated out of this project shall be a property of the Institute for Plasma Research. Replication or unauthorized copying / reproduction is not permitted.

5. Force Majeure:

FCIPT will not be responsible for any delay in executing the above proposed activity due to any reasons beyond its scope of control such as war, epidemics, natural disasters, labour problems/strike at our – our supplier's works, acts of GOD, or delay due to attaining test results of processed material, or any activity of other party linked with FCIPT's scope etc.

6. Liability:

FCIPT shall not be liable for any failures whether financial, technical or whatsoever, arising out of this agreement. M/s ABREF Pvt. Ltd. has been made aware and accepts that the scope of work under this agreement is purely research and development type and FCIPT will not be responsible for any loss arising due to use of such treated effluent. M/s ABREF Pvt. Ltd. shall not hold FCIPT liable for any damages, demands, expenses or losses asserted by M/s ABREF Pvt. Ltd. Limited or third party out of this agreement.

7. Jurisdiction:

Any and all disputes arising out of this contract shall be subject to Gandhinagar Jurisdiction.

We hope the above offer is in line with your requirement.

Thanking you,

For FCIPT, Institute for Plasma Research,

Anand Visani T. C. Cell



ABREF PRIVATE LIMITED

(MANUFACTURERS OF REFRACTORIES / KILN FURNITURE)

Regd. Office & Works: F-17, SIPCOT Complex, Gummidipoondi - 601 201. T.N., India
Ph.: 044-27922762 / 27922761 / 27924295 Telefax: 044-27922761

Website: www.abref.in E-mail: abref@vsnl.com

APL/R&D/001/1718

09.05.2017

To

Facilitation Centre for Industrial Plasma Technologies

Institute for Plasma Research,

A - 10/B, G.I.D.C, Sector -25,

Gandhinagar – 382 016

Gujarat, India

Sub:-Your offer for Feasibility studies on Interaction of Thermal Plasma with Fly Ash.

Ref: FCIPT/offer/024/16-17 dated 29.03.2017

Dear Sir,

We hereby accept your offer for Feasibility study (including, experiments charges, analysis charges, manpower overheads and consumables & contingencies charges) for Rs. 300000/- (Rupees Three Lakhs Only).

We are sending an Advance payment of Rs.240000/- (Rupees Two Lakhs Forty Thousands Only) vide SBI, Cheque No 764376 dated 09th May 2017, i.e 80% of your offer.

Thanking You,

For ABREF PRIVATE LIMITED

(T.N Jothiraj)

Managing Director

WORK ORDER

Loxim Industries Limited

Description : proposal for investigation of defects in coatings

Location : -

Department :

Cost Centre :

Vendor

: 100078 - INSTITUTE FOR PLASMA RESEARCH

Equipment :

Remarks

W.O. No.

: 2016-17/WOD/POL/00115

Date

: 07/01/2017

Completed On

Challan No.

Challan Date

: //

: //

Payment Terms : Advance

Other Terms

The specified work should be started on

: The work should be completed on or before

Srl. Job No.	Description	Start Date	Job Cost	Completion Date
1	Proposal for Investigation of defects in coatinfgs	11	515200.0000	11
	01 Investigation and analysis ofdefects in he coatings. x 01 Set Rs 448000.00 + Service Tax 15 % 67200.00 Total Amount In Rs 515200.00	eadlight reflector		
	As per your offer no Ref: FCIPT/ENQ/16-17/	28 Dt 03 01 2017		

TDS: Dedneted As Per Governost sombes & regulation.

Prepared By: PLPUR

07/01/2017

10:19:46

Updated By: PLPUR

07/01/2017

12:03:12

No. BT/PR12831/MED/30/1489/2015

GOVERNMENT OF INDIA MINISTRY OF SCIENCE & TECHNOLOGY DEPARTMENT OF BIOTECHNOLOGY

> Block 2, (6-8th Floors) CGO Complex, Lodhi Road, New Delhi- 110 003 Date: 13/06/2017

RELEASE ORDER

In continuation of this Department's sanction order of even number dated May 24, 2017 sanction of the President is hereby accorded, under Rule18 of the Delegation of Financial Powers Rule, 1978, for the release of Rs. 2170000.00 (Rupees Twenty One Lakhs Seventy Thousand Only) being the first year release for the project entitled "Expression analysis of inflammasome-forming NLRs in gliomas for identification of novel therapeutic interventions", being implemented by

- Dr. SUSHMITA JHA, Indian Institute of Technology Jodhpur, Room #3002, Administrative Block, Indian Institute of Technology, Old Residency Road, Ratanada, Jodhpur, Rajasthan India, - 342011, Rajasthan
- 2. Dr. Tejpal Gupta, Advanced Centre For Treatment Research & Education In Cancer, ACTREC, Tata Memorial Centre, Kharghar: 410210, Navi Mumbai, Mumbai - 410210, Maharashtra

The detailed break-up is as given below:

SNo Institute Name	Non R	ecurring	Total Release Amount (Rs)
	Equipment	Other	
Advanced Centre For Treatment Research & Education In Cancer	380000.00	0.00	380000.0
Indian Institute of Technology Jodhpur	1790000.00	At the time of Fig.	of Settlement of Meaning
	1790000.00	0.00	1790000.00

- 2. The amount of Rs. 2170000.00 /-(Rupees Twenty One Lakhs Seventy Thousand Only) will be directly credited by the Pay & Accounts Officer, DBT in the account as detailed below:
 - 1. Rs.1790000.00/- (Rupees Seventeen Lakhs Ninety Thousand Only) to The Director, Indian Institute of Technology Jodhpur, MBM Engineering College, Jodhpur - 342011,

Bank Name : HDFC Bank

Branch Name: Jodhpur Rajasthan A/c No. : 50200007479915 IFSC Code : HDFC0000142

MICR Code : 34224000

2. Rs.380000.00/- (Rupees Three Lakhs Eighty Thousand Only) to The Director, Advanced Centre For Treatment Research & Education In Cancer, KHARGHAR, Mumbai - 410210, Maharashtra

Bank Name : Central Bank of India

Branch Name: ACTREC Branch, Kharghar

A/c No. : 1797305746 IFSC Code : CBIN0284047 MICR Code : 400016114

No. BT/PR12831/MED/30/1489/2015

GOVERNMENT OF INDIA MINISTRY OF SCIENCE & TECHNOLOGY DEPARTMENT OF BIOTECHNOLOGY

> Block 2, (6-8th Floors) CGO Complex, Lodhi Road, New Delhi- 110 003 Date: 21 92 2020

RELEASE ORDER

In continuation of this Department's sanction order of even number dated May 24, 2017 sanction of the President is hereby accorded, under Rule18 of the Delegation of Financial Powers Rule, 1978, for the release of Rs. 1492500.00 (Rupees Fourteen Lakhs Ninety Two Thousand Five Hundred Only) being the second year release for the project entitled "Expression analysis of inflammasome-forming NLRs in gliomas for identification of novel therapeutic interventions", being implemented by

- Dr. SUSHMITA JHA, Indian Institute of Technology Jodhpur, Room #3002, Administrative Block Indian Institute of Technology, Old Residency Road, Ratanada, Jodhpur, Rajasthan India, - 342011, Rajasthan,
- Pr. Tejpal Gupta, Advanced Centre For Treatment Research & Education In Cancer, ACTREC, Tata Memorial Centre, Kharghar: 410210, Navi Mumbai, Mumbai - 410210, Maharashtra,

The detailed break-up is as given below:

SNo	Institute Name		Total Release Amount (Rs)					
		Manpower	Consumable	Travel	Contingency	Others	Overhead	
1	Advanced Centre For Treatment Research & Education In Cancer	345000.00	226000.00	0.00	25000.00	0.00	50000.00	646000.00
	Interest earned	amount of	Rs. 66797/-	reapprop	oriated to cor	sumables	head	<u> </u>
2	Indian Institute of Technology Jodhpur	0.00			WALLEST BY	1000		846500.00

- 2. The amount of Rs. 1492500.00 /-(Rupees Fourteen Lakhs Ninety Two Thousand Five Hundred Only) will be directly credited by the Pay & Accounts Officer, DBT in the account as detailed below:
 - 1. Rs.846500.00/- (Rupees Eight Lakhs Fourty Six Thousand Five Hundred Only) to The Director, Indian Institute of Technology Jodhpur, Department of Computer Science & Engineering MBM Engineering College, Jodhpur - 342011, Rajasthan

Bank Name : HDFC Bank

Branch Name: Jodhpur Rajasthan

A/c No.

: 50200007479915

IFSC Code : HDFC0000142

MICR Code : 34224000

2. Rs.646000.00/- (Rupees Six Lakhs Fourty Six Thousand Only) to The Director, Advanced Centre For Treatment Research & Education In Cancer, KHARGHAR, Mumbai - 410210, Maharashtra

Bank Name : Central Bank of India

Branch Name: ACTREC Branch, Kharghar

A/c No.

1797305746

IFSC Code

CBIN0284047

MICR Code : 400016114

3. The expenditure involved is debitable to:

Demand No. 87	Department of Biotechnology				
3425	Other Scientific Research 2019-2020				
3425.60	Others (Sub Major Head)				
Assistance to other Scientific Bodies (Minor Head)					
3425.60.200.29	Biotechnology Research and Development				
3425.60.200.29.17	Assistance for Research and Development				
3425.60.200.29.17.31	Grants -in-Aid General				

- 4. The Director, Advanced Centre For Treatment Research & Education In Cancer, Mumbai, Maharashtra and The Director, Indian Institute of Technology Jodhpur, Rajasthan will submit audited utilization certificates and statements of expenditure in respect of the above-mentioned amount.
- 5. As per Rule 236 (1) of GFR 2017, the accounts of all Grantee Institutions or Organisations shall be open to inspection by the sanctioning authority and audit, both by the Comptroller and Auditor General of India under the provision of CAG(DPC) Act 1971 and internal audit by the Principal Accounts Office of the Ministry or Department, whenever the Institution or Organisation is called upon to do so.
- 6. No International Travel will be undertaken from the sanctioned project grant unless specified
- 7. The Institute/Agency will keep the whole of the grant in a Bank Account earning interest, and the interest so earned should be reported to DBT in the Utilisation Certificate and Statement of Expenditure. The Interest so earned will be treated as created to the institute/Agency and shall be adjusted towards further instalment of the grant and or at the time of Final Settlement of Accounts.
- 8. In case the whole or a part of the amount of the grant-in-aid is being refunded, an interest rate at the rate of ten percent thereon shall be recovered. The Competent Authority has allowed a sum of Rs. 63935/- for IIT Jodhpur and Rs. 182152/- for ACTREC to be carried forward to the current financial Grantee institution is a public funded organization and the MOA has been signed. NO UC is pending

The other terms and conditions governing the financial sanction will remain unaltered.

- 9. The utilization certificate for the financial year 2918-15.. is enclosed herewith.
- 10. This issues under the powers delegated to Divisional Heads vide IFD order No. BT/04/2015-IFD dated 01.04.2019 and subsequently modified vide order of even number dated 10.05.2019. This has been noted in IFD at SAN No. 102/IFD/SAN/3753/2019-2020 dated February, 19 2020.

11. This sanction order has been noted at serial no. 113 ____ in the Register of Grants.

> (Dr. Sandhya डॉ. संघ्या आर. शिनीय

Dr. SANDHYA R. SHENOY वैज्ञानिक 'एफ' / Scientist 'F' बायोटेक्नोलॉजी विभाग / Deptt. of Biotechnology विज्ञान और प्रोद्यो. मंत्रालय/M/o Science & Tech. भरत सरकार, नई दिल्ली/Govt. of India, N. Delhi

To,

The Pay & Accounts Officer, Department of Biotechnology, New Delhi – 110 003.

Copy to:

- The Principal Director of Audit (Scientific Departments), DACR Building, New Delhi- 110
- Dr. SUSHMITA JHA(Project Co-ordinator), Room #3002, Administrative Block , Indian Institute of Technology Jodhpur, Department of Computer Science & Engineering MBM Engineering College, Jodhpur - 342011, Rajasthan
- 3 The Director, Advanced Centre For Treatment Research & Education In Cancer, KHARGHAR, Mumbai 410210, Maharashtra
- The Director, Indian Institute of Technology Jodhpur, Department of Computer Science & Engineering MBM Engineering College, Jodhpur 342011, Rajasthan
- Dr. Tejpal Gupta, Associate Professor, Radiation Oncology, Advanced Centre For Treatment Research & Education In Cancer, ACTREC, Tata Memorial Centre, Kharghar: 410210, Navi Mumbai, Mumbai 410210, Maharashtra
- 6 Cash Section, DBT (2 copies).
- 7 Sanction Folder.
- 8 File Copy.

(Dr. Sandhya R. Shenoy)

डॉ. संध्या आर. शिनोय**Scientist 'F'** Dr. SANDHYA R. SHENOY वैज्ञानिक 'एफ' / Scientist 'F' बायोटेक्नोलॉजी विमाग / Deptt. of Biotechnology

विज्ञान और प्रोद्यो, मंत्रालय /M/o Science & Tech. भारत सरकार, नई दिल्ली/Govt. of India, N. Delhi Mumbai 400 001.

COPY

Tel: 66657465 Fax: 22826092

e-mail:

figuard@sdtatatrust.com

10th September 2014

Dr. Sanjay Gupta
Cancer Research Institute
Advanced Centre for Treatment Research
and Education in Cancer
Tata Memorial Centre
Kharghar
Navi Mumbai 410210.

Dear Dr. Gupta,

This has reference to your online application for the year 2014-15 for financial assistance for your institutional research project titled "HISTONE DEACETYLASE INHIBITOR AS A POTENTIAL SENSITIZER FOR CHEMOTHERAPEUTIC DRUGS FOR INCREASING THEIR THERAPEUTIC GAIN IN GASTRIC CANCER: A PRECLINICAL STUDY" to be carried out at the Advanced Centre for Treatment Research and Education in Cancer, Navi Mumbai.

Your research project was scrutinized by Members of our Indian Scientific Advisory Committee (ISAC), and you were, thereafter, invited to make a presentation before the ISAC at our July 19, 2014 interview meeting.

We are glad to inform you that on the recommendation of the Members of our Indian Scientific Advisory Committee, the Trustees have sanctioned a partial financial support of Rs.5,00,000/- per year, for your above 2-year research project. The grant will be disbursed in two equal instalments in the following manner:

YEAR	AMOUNT (Rs.)
2014-2015	5,00,000/-
2015-2016	5,00,000/-
Total:	10,00,000

Our cheque for Rs.5,00,000/- drawn in favour of the **DIRECTOR-ACTREC**, **TMC**, is enclosed, being the grant for the first year, with a request to kindly acknowledge receipt in due course.

1914114



PAREXEL International Clinical Research Private Limited

1st Floor, Wing A, Indiqube Alpha Building Kadubeesanahalli Village, Panathur Junction, Marathahalli Sarjapur Road, BENGALURU, INDIA-560 087 t +91 80 6716 9300, f +91 80 6716 9301

WWW.PAREXEL.COM

CIN: U74220KA2006PTC039077

22 Aug 2016

207050/2016/357

To,

Dr. Rajendra Badwe

Department of Surgical Oncology,

Tata Memorial Centre,

Dr. E. Borges Road, Parel

Mumbai, Maharashtra 400012

India

Puma Protocol Title: 3144A2-3005-WW, B1891005, A Randomized, Open-label, Two-arm study of Neratinib plus Paclitaxel Versus Trastuzumab plus Paclitaxel as first-line treatment for Erbb-2positive Locally Recurrent or Metastatic Breast Cancer, 207050 Site#275

Subject: Study payment

Dear Dr. Goswami,

Please find the enclosed Cheque

Cheque Number	Dated	Invoice Number	Amount
100758	16-Aug-2016	EDC/HKI-3005/Invoice 2015/005668-04 EDC/HKI-3005/Invoice 2015/005668-05 EDC/HKI-3005/Invoice 2016/005668 - 01 EDC/HKI-3005/Invoice 2016/005668 - 02	Rs 3,88,628.00

of The Honkong and Shanghai Banking Corporation Limited drawn in the favour of TATA MEMORIAL HOSPITAL, towards the payment of Invoice dated 18-July-2016 for the above referenced study.

Please acknowledge by signing the acknowledgement of receipt below and kindly send us the scan copy via email.

Thanking you for your support towards the study.

Yours sincerely,

hyadhena:V

Annierry Mathews Sr. Clinical Research Associate

PAREXEL International Clinical Research Pvt. Ltd.

Tel: 91-80-67169316 Mobile - 95352 74851

I hereby acknowledge receipt of above CIOMS report(s).

Kohimi Hawaldan

Prograldar

Transaction 1D:-201600121

Please sign and date above for the acknowledgement of receipt and send back this cover letter to Anmerry by fax: +91 80 6716 9301 or scanned by email: Anmerry Mathews@parexel.com



恒 原 原 子 能 机 构 International Atomic Energy Agency Agence internationale de l'énergie atomique Международное агентство по атомной энергии Organismo Internacional de Energía Atómica

Atoms For Peace

Vienna International Centre, P.O. Box 100, A-1400 Vienna, Austria Phone: (+43 1) 2600 • Fax: (+43 1) 26007 E-mail: Official.Mail@iaea.org • Internet: http://www.iaea.org

IAEA Research Contract No: 16563

Research Contract

This Research Contract is made between the International Atomic Energy Agency (herein after referred to as the "IAEA") whose address is Wagramer Strasse 5, P.O. Box 100, A-1400 Vienna, Austria and the Advanced Centre for Treatment Research & Education in Cancer (ACTREC) (herein after referred to as the "Contractor") whose address is Advanced Centre for Treatment Research & Education in Cancer (ACTREC) Tata Memorial Centre Kharghar NAVI MUMBAI, Mumbai 410 210 INDIA.

Whereas

the IAEA is authorized under its Statute and the decisions of its competent organs to encourage and assist research on, and the development and practical applications of atomic energy for peaceful purposes throughout the world by entering into contracts for research and development.

Whereas

the Contractor is able and willing to carry out a Research Project desired by the IAEA;

Now, therefore

the IAEA and the Contractor hereby agree as follows:

1. Scope of the Research Project

a) The Contractor shall undertake a Research Project entitled 'CRP on Resource Sparing Curative Radiotherapy for Locally Advanced Squamous Cell Cancer of Head and Neck'.

The Chief Scientific Investigator shall be Mr. Gupta, Tejpal.

- b) The programme of work shall be:
- To get the protocol approved by the local Ethics Committee, once it has been finalised.
- To attend the first RCM in 2011 to discuss final arrangements.

- To begin identifying, recruiting, treating and following patients.
- To submit filled forms to the data managing centre.

The programme of work may be further detailed by exchange of letters between the IAEA and the Contractor.

2. Duration of Research Project

The Research Project shall commence on 2010-11-15 and shall extend for a period of one year. It may be renewed for a further period of one year by the mutual agreement of the Parties.

3. Reports

The Contractor shall submit to the IAEA a progress report on the Project nine (9) months after its commencement. A final report shall be submitted to the IAEA upon the completion of the Project. In the event of an extension of this Contract, necessary modifications shall be made as to the Contractor's obligation in respect to the final report. These reports shall be submitted in English and shall be prepared in accordance with the Annex to this Contract concerning Preparation of Reports.

4. Rights to reports and intellectual property

- a) The reports to be submitted by the Contractor to the IAEA pursuant to this Contract shall be the exclusive property of the IAEA. The Contractor hereby assigns to the IAEA all intellectual property rights to such reports and any results emanating from the Research Project. This assignment shall include the right to publish the reports and any results emanating from the Research Project in any form and in any language and the right to transfer to third parties any rights mentioned herein.
- b) The Contractor and its staff may publish any results of the Research Project, provided that any such publication shall include an appropriate acknowledgement of the contribution of the IAEA. The Contractor shall not publish any unpublished information received from the IAEA.
- c) All results of the Research Project, including any inventions or discoveries arising there from, shall be made available widely for the development and practical application of atomic energy for peaceful purposes throughout the world. To accomplish this purpose the IAEA and the Contractor shall cooperate through prompt and extensive publication and by other appropriate means to prevent any restriction of the free use of such results. The IAEA or the Contractor and its staff may obtain a patent or similar protection of such results provided that the owner of such patent agrees to make the invention freely useable in the territory of all Member States of the IAEA without charge or any other restriction. The IAEA and the Contractor shall assist each other in obtaining any patent or similar protection that either may wish to obtain under the above conditions. Arrangements shall be made to avoid any conflicting applications for patents.
- d) The Contractor undertakes to take necessary steps to ensure that every person who participates in the Research Project shall be fully informed of the obligations contained in this clause and agrees to be bound by them.

5. IAEA Contribution

The IAEA shall contribute a sum not exceeding €7 000 (Seven Thousand)

6. IAEA's Financial Obligations

The amount to be contributed by the IAEA pursuant to clause 5 of this Contract shall be paid to the Contractor in two instalments as follows:

- (i) An initial payment equivalent to €3 500 (Three Thousand Five Hundred) shall be paid on the entry into force of this Contract.
- (ii) A final payment equivalent to €3 500 (Three Thousand Five Hundred) shall be paid to the Contractor upon the completion of the Research Project and on the certification by the appropriate officer of the IAEA for the Project that the reports required under clause 3 of this Contract have been received in due time and accepted by the IAEA.

Payment shall be made to: Tata Memorial Centre - ACTREC

The Parties may provide through an exchange of letters made pursuant to this Contract that a part or parts of the payment to be made by the IAEA under this Contract shall be used for a particular purpose. In that case, the part or parts of the payment shall be used only for the prescribed purpose.

The IAEA and the Contractor may agree that a part of the payment from the IAEA prescribed in clause 5 shall be made into the Research Institutes Trust Fund to the Contractor's credit for use in providing to the Contractor items of equipment or expendable supplies required for the execution of the Project as may be stated in an exchange of letters. The Trust Fund shall be administered by the IAEA in accordance with the IAEA's Financial Regulations and Rules and the additional criteria set forth in the Annex to this Contract concerning the Research Institutes Trust Fund.

7. Title to equipment

The Contractor hereby agrees that title to the equipment provided by the IAEA pursuant to this Contract shall be vested in the IAEA until the completion of the Research Project. At that time, the IAEA may transfer to the Contractor without further charge provided that the appropriate officer designated by the IAEA for the Project certifies that the reports required under clause 3 of this Contract have been received in due time and accepted and that the Contractor has arranged with its home government that no customs or similar payments shall be made by the IAEA in connection with the transfer of title.

8. Other responsibility of the Contractor

- a) The Contractor agrees that the funds provided by the IAEA under this Contract shall be used solely in connection with the Research Project.
- b) The Contractor undertakes to promptly notify the IAEA of any change in the status of the Chief Scientific Investigator in relation to the Research Project.
- c) The Contractor shall observe any pertinent health and safety standards and regulations that are communicated to the Contractor, except as otherwise agreed by exchange of letters.
- d) The Contractor shall be responsible for the safety and maintenance of any equipment provided in relation to this Contract and to which the IAEA retains title. If requested by and at the expense of the IAEA, the Contractor shall at the end of the period of the Research Project make the necessary arrangements for the shipment of any equipment placed at his disposal.

9. Indemnification

The Contractor shall indemnify, hold and save harmless and defend, at its own expense, the IAEA, its officials, agents, servants and employees, from and against all suits, claims, demands and liability of any nature or kind, including their costs and expenses, arising out of the acts or omissions of the Contractor or its employees or sub-contractors in the performance of this Contract. The provision shall extend to claims and liability in the nature of workmen's compensation claims and those arising out of the use of patented inventions or devices.

10. Assignment

The Contractor shall not assign, transfer, pledge or make other disposition of this Contract or any part thereof or of any of the Contractor's rights, claims or obligations under this Contract except with the prior written authorization of the IAEA.

11. Sub-contracting

In the event the Contractor requires the services of sub-contractors, the Contractor shall obtain the prior written approval and clearance of the IAEA for all sub-contractors. The approval of the IAEA of a sub-contractor shall not relieve the Contractor of any of its obligations under this Contract. The terms of any sub-contract shall be subject to and in conformity with the provisions of this Contract.

12. Use of name, emblem or official seal of the IAEA

The Contractor shall not advertise or otherwise make public the fact that it is a Contractor with the IAEA. Also the Contractor shall, in no other manner whatsoever use the name, emblem or official seal of the IAEA or any abbreviation of the name of the IAEA in connection with its business or otherwise.

13. Status of Contractor

The Contractor shall have the legal status of an independent Contractor. The personnel of the Contractor and any of its sub-contractors shall not be considered in any respect as being agents or employees of the IAEA.

14. Privileges and immunities

Nothing in this Contract shall be construed as a waiver of the privileges and immunities accorded to the IAEA by its Member States.

15. Annexes

The Annex(es) referred to in this Contract shall form an integral part of this Contract.

16. Force majeure and other changes in conditions

a) In the event of and as soon as possible after the occurrence of any cause constituting force majeure, the Contractor shall give notice and full particulars in writing to the IAEA of such occurrence or change if the Contractor is thereby rendered unable, wholly or in part, to perform its obligations and meet its responsibilities under this Contract. The Contractor shall also notify the IAEA of any other changes in conditions or the occurrence of any event which interferes or threatens to interfere with its performance of the Contract. On receipt of the notice required under this Article, the IAEA shall take such action as, in its sole discretion, it considers to be appropriate or necessary in the circumstances, including the granting to the Contractor of a reasonable extension of time in which to perform its obligations under the Contract.

- b) If the Contractor is rendered permanently unable, wholly or in part, by reason of force majeure to perform its obligations and meet its responsibilities under this Contract, the IAEA shall have the right to suspend or terminate this Contract on the same terms and conditions as are provided for in Article 17, "Termination", except that the period of notice shall be seven (7) days instead of thirty (30) days.
- c) Force majeure as used in this Article shall mean any unforeseeable circumstance or circumstances beyond the Parties' control, including but not limited to armed conflicts, acts of governments, delays in transport or customs clearance, damage incurred during transport, shortage of energy, shortage of raw materials, spoilage due to force majeure of a major or essential component, and strikes.

17. Termination

Either Party may for valid cause terminate this Contract, in whole or in part, upon thirty (30) days' notice to the other Party. Where notice of termination is given, the Contractor shall, as from the date of receipt of such notice from the IAEA or as from the date of such notice by the Contractor, as appropriate, take immediate steps to bring the work and services to a close in a prompt and orderly manner, shall reduce expenses to a minimum and shall not undertake any forward commitment. On termination the IAEA shall pay the Contractor for work satisfactorily performed prior to termination and in conformity with the express terms of this Contract.

. 18. Settlement of Disputes

Any disputes arising out of or relating to interpretation or implementation of this Contract, which cannot otherwise be settled by the Parties, shall be referred by either Party to arbitration for settlement in accordance with the UNCITRAL Arbitration Rules as in force at the date the dispute is referred to arbitration. The number of arbitrators shall be one. The place of arbitration shall be Vienna, Austria. The language of arbitration shall be English. The decisions of the arbitrator shall be final and binding on the Parties.

19. Amendment

No modification of, or changes to, this Contract or waiver of any provision shall be valid unless made in writing and approved by the duly authorized representatives of the Parties.

20. Entry into force

This Contract shall enter into force on the date of the last signature by the representatives of the Parties.

IAEA:

Teresa Benson

Head, Research Contracts Administration Section Dept. of Nuclear Sciences & Applications

Lusa/Ben

Date: 2010-11-18

Contractor:

Head of Institute

Education Tala Memo Navi M

Date 29.11-2010

Chief Scientific Investigator

Date 29.11.2010

PLEASE PROVIDE THE FOLLOWING BANK DETAILS:

NAME OF INSTITUTE'S BANK - CENTRAL BANK OF INDIA

BANK ADDRESS - CBD BELAPUR BRANCH, ACTREC EXTENSION COUNTE

ACCOUNT NAME (IN THE NAME OF THE INSTITUTE) - TATA MEMORIAL CENTRE - ACTREC

ACCOUNT NO - 1797305746

BANK ROUTING NO (SORT CODE, BIC, SWIFT CODE OR IBAN) - - CV 1 NO 283/54

RTGS/IFSC Gde: CBIN0013154

Incomplete bank details may result in a delay of payment. SWIFT CODE : EBININBBOSB

Jepal Guble 29/11/2010

P Kamaia

tejpalgupta@rediffmail.com on behalf of tejpal gupta [tejpalgupta@rediffmail.com] Wednesday, August 17, 2016 3:08 PM pkamala@actrec.gov.in accounts@actrec.gov.in HYPNO disbursements from IAEA

From: Sent: To: Cc: Subject:

Dear Mrs Kamala

Please find the disbursements from IAEA on HYPNO study over the last few years with reference

number and dates.

The first instalment was of 3500 Euros in 2010, subsequently we have received 3500 + 3750 Euros (2012), 3750 + 3750 Euros (2013), 3750 + 3750 Euros (2014) and 3750 + 5000 Euros

(disbursed for 2015, but actually received in <u>Jan 2016</u>). Please confirm that the same has been credited appropriately to the HYPNO account at ACTREC.

Tejpal

Ne: Forwarded message attached

-- Original Message --

From: W

To: W Cc: W

Subject: W

Welcome to Rediffmail: Inbox

Rediffmail

Mailbox of tejpalgupta@rediffmail.com

Print Cancel

From: <K.I.Hopkins@iaea.org>

To: <tejpalgupta@rediffmail.com>

Subject: Re: Research Contract 16563 (HYPNO) - Disbursements to Tata Memorial Centre, Mumbai

Date: Thu, 11 Aug 2016 14:24:28 IST

p	urc	hase	ord	ler '	total	1: (39	500

Invoice total: € 34 500

PO Number	PO Date	PO Amount	Invoice	Invoice Date	Invoice Amount
201040748	2010-11-23	€ 7 000	RC16563F	2010-12-08	€ 3 500
			ERS-19-APR-12-6520	2012-04-19	€ 3 500
201105726	2011-11-25	€ 7 500	ERS-19-APR-12-6524	2012-04-19	€ 3 750
			ERS-23-OCT-13-23930	2013-10-23	€ 3 750
CR-IND-16563-R2-1	2013-08-06	€ 7 500	ERS-17-OCT-14-30941	2014-10-17	€ 3 750
			ERS-23-OCT-13-23930	2013-10-23	€ 3 750
CR-IND-16563-R3-1	2014-09-17	€ 7 500	ERS-25-JAN-16-40925	2016-01-25	€ 3 750
			ERS-17-OCT-14-30941	2014-10-17	€ 3.750
CR-IND-16563-R4-1	2015-12-15	€ 10 000	ERS-25-JAN-16-40925	2016-01-25	€ 5 000

Deep Mrk Komak,

THEA disburses money in instalments. The first instalment

ope you are well.

Stop Euros Came, Une Die 2010. Subsequently the runnains

stope Euros + 3750 Euros of nenewal Contract who disbursed in 2012.

Stope The Similarly with Mark Yearwal 3750+375 Euros in 2013 are 3750+375 Euros

at emailing research contracts Research Contracts Administration—Contact Point Research Contracts Research Contract Research Resear

ase be tactful when discussing with others. I got your rise through in better times. No one else can get it, parently we are hugely overdrawn in Human Health. Frankly you well deserved a rise given the recruitment algorithms of ordering your with the control of the control of

bay – very best wishes, and thank you for being such excellent recruiters.

tejpalgupta@rediffmail.com [mailto:tejpalgupta@rediffmail.com]

Wednesday, 10 August 2016 03:25

OPKINS, Kirsten Isabel LYAKOV, Oleg

ect: Research Contract 16563 (HYPNO) - Disbursements to Tata Memorial Centre, Mumbai

Dr Hopkins and Ms Olga

पी.ए.बी.एक्स./PABX: 26588980, 26588707, 26589336, 26589745, 26589414

तार / GRAM : विज्ञानी / SCIENTIFIC

Web-site : www.icmr.nic.in icmrhqds@sansed.nic.in

Date: 17.12.2016



भारतीय आयुर्विज्ञान अनुसंधान परिषद INDIAN COUNCIL OF MEDICAL RESEARCH

वी. रामलिंगस्वामी भवन, अन्सारी नगर, पोस्ट बॉक्स 4911, नई दिल्ली - 110 029 V. RAMALINGASWAMI BHAWAN. ANSARI NAGAR. POST BOX 4911. NEW DELHI - 110 029

No. 53/13/2013-CMB/BMS

Subject:- Payment of 1st & 2nd installment of the 2nd year grant-in-aid for the project entitled "Understanding the cross talk between mesenchymal stromal cells and leukemic stem cells in Acute Myeloid Leukemia: Implications in disease biology and therapy".

Memorandum

The Director General of the Council sanctions the payment of Rs.15,04,904/- [Rupees Fifteen Lakh Four Thousand Nine Hundred Four Only] as the 1st & 2nd installment of the 2nd year grant for the period of one year from 01.03.2016 to 28.02.2017 for incurring expenditure in connection with the above-mentioned project.

The amount of Rs.15,04,904/- may be debited under the provision of Rs.15,04,904/made on the above mentioned project for the year 2016-17.

The unspent balance of Rs. 7,32,251/- is already available with PI from last year grant. A formal bill for Rs. 15,04,904/- is sent herewith after the adjustment of unspent balance net payment by NEFT/ RTGS for Rs.7,72,653/- in favour of the Director, Advanced Centre for Treatment Research and Education in Cancer(ACTREC), Kharghar, Navi Mumbai. This issued with the concurrence of the Finance Divn, vide RFC No. BMS/Adhoc/78/2014-15 dated: 09.03.2015.

SRF @ Rs. 28,000/- p.m.	=	Rs. 4,36,800/-
+ HRA 30% Rs. 8,400		
Contingency @ Rs.10,00,000/-p.a.		Rs. 10,00,000/-
Travel @ Rs. 25,000/- p.a.	=	Rs. 25,000/-
Overhead Charges 3%	=	Rs. 43,104/-
Total	= ,	Rs. 15,04,904/-
Less: Unspent balance	=	Rs. 7,32,251/-
Total released	=	Rs. 7,72,653/-

(Ishwar Likhar) Administrative Officer

For Director General

Accounts V. ICMR

Copy to:

The Director, Advanced Centre for Treatment Research and Education in Cancer(ACTREC), Tata Memorial Centre Sector22, Kharghar, Navi Mumbai-410210. The grant has been sanctioned on the conditions laid down in out letter referred to

2 Dr. Jyoti A Kode, Scientific Officer-F, Chiplunkar Lab, Advanced Centre for Treatment Research and Education in Cancer(ACTREC), Tata Memorial Centre Sector22, Kharghar, Navi Mumbai-410210.

It is requested that an audited statement of account together with utilization certificate of the grant received and utilized in _____ may kindly be sent to this office in due course.

3 IRIS Cell No. 2012-0839

Central File

Administrative Officer For Director General

BUDGET STATEMENT

2016-17

Subject: Research Project entitled "Understanding the cross talk between mesenchymal stromal cells and leukemic stem cells in Acute Myeloid Leukemia: Implications in disease biology and therapy" under Dr. Jyoti A Kode, Scientific Officer-F, Advanced Centre for Treatment Research and Education in Cancer(ACTREC), Kharghar, Navi Mumbai.

(01.03.2016 to 28.02.2017)

	Total Saliction	=	Rs.15.04.904/-
	Total sanction		Rs. 43,104/-
4	Overhead charges 3%	_	
	11aver (@ NS. 25,000/- p.a.	=	Rs. 25,000/-
3	Travel @ Rs. 25,000/- p.a.	-	Rs. 10,00,000/-
2	Contingency @ Rs. 7,00,000/- p.a.	_	D- 40.00.000/
	+ HRA @ 30% Rs.8,400/- p.m.		13. 4,30,000/-
1	SRF @ Rs. 28,000/- p.m.	_	Rs. 4,36,800/-

Total budget allotment of Rs. 15,04,904/- [Rupees Fifteen Lakh Four Thousand Nine Hundred Four Only]

RFC No. BMS/Adhoc/78/2014-15 dated: 09.03.2015

F.No. 53/13/2013-CMB/BMS

Received Contents

Administrative Officer for Director General

कैक्स/FAX

पी.ए.बी.एक्स./PABX: 26588980, 26588707, 26589336, 26589745, 26589414

तार / GRAM : विज्ञानी / SCIENTIFIC : www.icmr.nic.in

Web-site

: icmrhqds@sansed.nic.in



भारतीय आयुर्विज्ञान अनुसंधान परिषद INDIAN COUNCIL OF MEDICAL RESEARCH

वी. रामलिंगस्वामी भवन, अन्सारी नगर, पोस्ट बॉक्स 4911, नई दिल्ली - 110 029 V. RAMALINGASWAMI BHAWAN. ANSARI NAGAR. POST BOX 4911. NEW DELHI - 110 029

No. 53/13/2013-CMB/BMS

Date: 16.12.2016

21

To,

Dr. Jyoti A Kode, Scientific Officer-F, Chiplunkar Lab, Advanced Centre for Treatment Research and Education in Cancer(ACTREC), Tata Memorial Centre Sector22, Kharghar, Navi Mumbai-410210

Subject:- Research project entitled, "Understanding the cross talk between mesenchymal stromal cells and leukemic stem cells in Acute Myeloid Leukemia: Implications in disease biology and therapy".

Sir/Madam.

Please refer to your letter dated 14.06.2016 forwarding the clarification regarding utilization certificate and annual statement of expenditure of the above mentioned project.

The Director-General of the ICMR sanctions continuation of the above mentioned project for further period of 2nd year w.e.f. 01.03.2016 to 28.02.2017 with budget allotment of Rs. 15,04,904/-. The terms and conditions will remain same as mentioned in the office letter of even number dated 19.03.2015.

Thanking you,

Yours faithfully

[Ishwar Likhar] Administrative Officer For Director-General

1 Copy together with a copy of the budget statement forwarded for information to the Director, Advanced Centre for Treatment Research and Education in Cancer(ACTREC), Tata Memorial Centre Sector22, Kharghar, Navi Mumbai-410210.

2 Copy together with budget statement forwarded to Accounts Section-V, ICMR information and further necessary action

3 Copy together with copy of the budget statement forwarded to the Finance Section ICMR for information.

IRIS Cell No. 2012-0839

Administrative Officer For Director-General Telegram: "SCIENTIFIC"

Phone: 26588980,26588707

INDIAN COUNCIL OF MEDICAL RESEARCH ANSARI NAGAR NEW DELHI-110029

Dated:-

To,

The Branch Manager, Canara Bank, South Ext. Part-II, New Delhi-110029

Sir,

The following transfers may kindly be effected Telegraphically by the Branch Manager of the Canara Bank, South Extension, Part-II for crediting the amount into accounts of the following units:-

1.	Details of Bank	Amounts	Name of the Bank	To be Credited to
2.	Branch	Rs.8,14,936/-	CENTRAL BANK OF INDIA	the Account of
		13.0,14,930/-	, jew pojerovio	The Director, Advance Centre for Treatment Research
			MUMBAI	Education in Cancer, Mumbai – 410210.
3.	Account Number		1797305746	
4.	IFCS Code		CBIN0284047	
5.	MICR Code		400016114	

A Cheque No. 215135 dated 29/16

for Rs... Eight lakhs fourteen thousand nine hundred thirty six only...... is enclosed.

It is also pointed out that no charge may be debited to our account for the above remittance as the Council transacts Govt. funds in public interest.

Yours faithfully

(Section Officer)

Copy to: -

- 1. A.O. BMS (ICMR)
- 2. File No.53/13/2013-BMS
- 3. Dr. Jyoti A Kode, Scientific Officer E, Chiplunkar Lab, Advanced Centre for Treatment Research and Education in Cancer, (ACTREC), Kharghar Navi Mumbai- 410210.
- 4. Sub. Understanding the cross talk between mesenchymal stormal cells and leukemic stem cells in Acute mudeloid..

7535

Reid 31/12/12



NO. SR/FT/LS-111/2012 SCIENCE & ENGINEERING RESEARCH BOARD

Technology Bhavan New Mehrauli Road New Delhi – 110 016. Dated: December 18, 2012

ORDER

Subject: Financial Sanction of the research project titled "MR-PET guided biologically optimised interstitial brachytheraphy for postoperative recurrent cervical cancers" under the guidance of Dr.(Ms.) Supriya Chopra, Deptt. of Radiation Oncology, Advanced Centre of Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Khargar, Navi Mumbai-410210, Maharashtra.

Sanction of Science and Engineering Research Board (SERB) is hereby accorded to the above mentioned project at a total cost of Rs. 23,53,000/- (Rs.Twenty Three Lakh Fifty Three Thousand Only) with break-up of Rs. 3,34,000/- under Capital head and Rs. 20,19,000/- under General head for a duration of three years. The items of expenditure for which the total allocation of Rs. 23,53,000/- has been approved for a period of three years, are given below:

SI. No	Head	Total(in Rs.)
A	Non-recurring (Capital Items)	
1	Equipment	3,34,000
	Nucleotron Compitable needles	and a thing of the state of the
A'	Total (Capital)	3,34,000
В	Recurring Items (General)	er adronación de l'existe
1	General – A	
	(Manpower, Consumables, Travel, Contingencies, Analytical/Biological Analysis Charges)	17,19,000
2	General – B	3,00,000
	(Overhead Charges)	
B'	Total (General)	20,19,000
C	Total cost of the project (A' + B')	23,53,000

- 2. Sanction of the SERB is also accorded to the payment of Rs. 3,34,000/- (Rs.Three Lakh Thirty Four Thousand Only) under 'Grants for creation of Capital assets' and Rs. 50,000/- (Rs.Fifty Thousand Only) under 'Grants-in-aid -General' to the TATA MEMORIAL CENTRE, ACTREC, MUMBAI being the grant for the year 2012-13 for implementation of the said research project.
- 3. The expenditure involved is debitable to

Grant-in-aid for the year 2012-13 (Plan Expenditure- Capital) - Rs. 3,34,000/-

&

Grant-in-aid for the year 2012-13 (Plan Expenditure- General) - Rs. 50,000/-

This release is made under OYS Scheme.

- 4. The Sanction has been issued with the approval of the competent authority under delegated powers and vide Diary No.SERB/F/5190/2012-13 dated 18.12.2012.
- 5. Sanction of the grant is subject to the conditions as detailed in Annexure I.
- Overhead expenses are meant for the host Institute towards the cost for providing infrastructural facilities and general administrative support etc. including benefits to the staff employed in the project.

Longrabulations Subriya.

- 7. While providing operational flexibility among various subheads under head General-A, it should be ensured that not more than Rs. 1.5 lakh each should be spent for travel and contingency.
- 8. The total release amount of Rs. 3,84,000/- (Rs.Three Lakh Eighty Four Thousand Only) will be drawn by the Drawing & Disbursing Officer of the SERB and will be disbursed by means of cheque/DD favoring "TATA MEMORIAL CENTRE, ACTREC, MUMBAI" and will be sent to Director, Advanced Centre of Treatment, Research and Education, Tata Memorial Centre, Khargar Node, Navi Mumbai-410210.
- 9. As per rule 211 of GFR, the accounts of project shall be open to inspection by sanctioning authority/audit whenever the institute is called upon to do so.
- 10. The institute will furnish to the SERB, New Delhi, Utilization certificate and an audited statement of accounts pertaining to the grant immediately after the end of each financial year.
- 11. The manpower sanctioned in the project, if any is co-terminus with the duration of the project and SERB will have no liability to meet the fellowship etc. beyond the duration of the project,
- 12. The institute will maintain separate audited accounts for the project. It is found expedient to keep a part or whole of grant in a separate bank account earning interest. The interest earned should be reported to the SERB, New Delhi. The interest thus earned will be treated as a credit to the institute to be adjusted towards further installment of the grant.
- 13. The sanctioned equipments would be procured as per GFR and its disposal would be done with prior approval of SERB.
- 14. The project File no. SR/FT/LS-111/2012 may also be mentioned in all research communications arising from the above project with due acknowledgement of SERB.
- 15. As this is the first grant being released for the project, no previous U/C is required.

(Jacob V.V.) Scientist-D

Copy forwarded for information and necessary action to: -

.1	The Principal Director of Audit, A.G.C.R. Building, IIIrd Floor I.P. Estate, Delhi-1	10002
2	Copy with two spare copies of the sanction to the Drawing and Disbursing Office Delhi	cer, SERB, New
3	Pay Accounts Officer, SERB, New Delhi	
4	Sanction Folder, SERB, New Delhi.	1
5	File Copy	
6	Dr.(Ms.) Supriya Chopra Deptt. of Radiation Oncology Advanced Centre of Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Khargar Navi Mumbai-410210, Maharashtra	Great
7	(Start date of the project may be intimated by name to the undersigned.) Director, Advanced Centre of Treatment, Research and Education, Tata Memorial Centre, Khargar Node, Navi Mumbai-410210, Maharashtra (Receipt of Cheque/DD may be intimated by name to the undersigned.)	

(Jacob V.V.) Scientist-D

count Department

Supriya Chopra [supriyasastri@gmail.com] Thursday, 15 October, 2015 6:55 PM Account Department Fwd: RTGS/NEFT UTR/ TRANS No. – File No. SR/FT/LS-111/2012

From: "Finance Wing, SERB" < finance@serb.gov.in>

Subject:

Subject: RTGS/NEFT UTR/ TRANS No. - File No. SR/FT/LS-111/2012

0: <a href="mailto:schopmailto

Mr/Ms/Prof/Dr. SUPRIYA CHOPRA D/o RADIATION ONCOLOGY. TATA MEMORIAL CENTRE, ACTREC, NAVI MUMBAI - 410210

Subject: RTGS/NEFT UTR/ TRANS No. - File No. SR/FT/LS-111/2012

Sir/Madam.

I am directed to refer to Science & Engineering Research Board (SERB) sanction order no. SR/FT/LS-111/2012dated 23-09-2015 and forward herewith the following for information

RTGS/NEFT UTR/Transaction no.: UBINH15286032273 / SAA160600623dated 13-10-2015.

₹700000/- (RUPEES SEVEN LAKH ONLY)

Bill no. GIA/3699 dated 03-10-2015

SERB/F/4325/2015-16

CONFIRMATION OF RECEIPT OF GRANTS MAY KINDLY BE SENT BY EMAIL ONLY.

SEPARATE Utilization Certificates (UCs) for Recurring and Non-Recurring Grants (even if <u>DISBURSED BY SERB THROUGH ONE SANCTION ORDER</u> for your project) should be sent directly to the grant Sanctioning Authority by name (signatory of the sanction order) within twelve months of the closure of the financial year in which the grants were released irrespective of whether the subsequent instalment of grant is due for release

However, if any unspent balance is to be refunded, kindly ensure that the unutilized amount may be refunded immediately by way of an afc payee cheque/DD drawn in favour of "Fund for Science & Engineering Research", payable at New Delhi and forwarded to the undersigned at the address given below:

तार / GRAM: विज्ञानी / SCIENTIFIC Web-site : www.icmr.nic.in : icmrhqds@sansad.nic.in

Date:01.02.2017



भारतीय आयुर्विज्ञान अनुसंधान परिषद INDIAN COUNCIL OF MEDICAL RESEARCH

वी. रामलिंगस्वामी भवन, अन्सारी नगर, पोस्ट बॉक्स 4911, नई दिल्ली - 110 029 V. RAMALINGASWAMI BHAWAN. ANSARI NAGAR. POST BOX 4911. NEW DELHI - 110 029

No. 82/14/2012/PHGEN(TF)/BMS

Subject:- Payment of Contingency of the 1st year grant for the project entitled "Pharmacogenetic study of commonly used anticancer drugs: implications of ADME gene polymorphisms in the treatment of Indian cancer patients."

Memorandum

The Director General of the Council sanctions the payment of Rs. 35,39,904/- [Rupees Thirty Five Lakh Thirty Nine Thousand Nine Hundred Four Only] as the Contingency of the 1st year grant for the period of one year from 01.02.2017 to 31.01.2018 for incurring expenditure in connection with the above-mentioned project.

The amount of Rs. 30,90,000/- may be debited under the provision of Rs. 35,39,904/made of on the above mentioned project for the year 2016-17.

A formal bill for Rs. 35,39,904/- is sent herewith for payment by NEFT/ RTGS for Rs. 30,90,000/- in favour of the Director, Advanced Centre for Treatment, Research & Education Cancer(ACTREC), Tata memorial Centre, Navi Mumbai. This issued with the concurrence of the Finance Divn, vide RFC No. BMS/ADHOC/4/2016-17 Date: 30.01.2017.

	Total	=	Rs.30,90,000/-
2	Overhead Charges 3%	=	Rs. 90,000/-
1	Contingency @ Rs. 30,00,000/- p.a.	=	Rs.30,00,000/-

(IshwarLikhar) Administrative Officer For Director General

Accounts V. ICMR

- 1. Copy to: the Director, Advanced Centre for Treatment, Research & Education Cancer(ACTREC), Tata memorial Centre, Kharghar, Navi Mumbai-410210. The grant has been sanctioned on the conditions laid down in out letter referred to above.
- 2. Dr. Vikram Gota, Associate Professor & Scientific Officer-F. Clinical Pharmacology. Advanced Centre for Treatment, Research & Education Cancer(ACTREC), Tata memorial Centre, Kharghar, Navi Mumbai-410210. The Salary will be released on receipt of joining report of staff.
- 3. IRIS Cell No. 2012-0812
- 4. Central File

Administrative Officer For Director General

Acknowledgement Copy

Item No___ Project No_221

Amendment

To.

Dated: 04-11-2016

Dr. Vedang Murthy

Member Secretary

TMC-ACTREC Institutional Ethics Committee (IEC)

Subject: Submission of the amended research proposal: Project No. 221

Bear Dr Murthy,

Thank you for approving the above project. We request you to consider the amendments in the attached documents. We have included 2 more co-investigators, modified the budget and made some changes in the inclusion criteria and methodology. We have not started the accrual as yet.

Hence we are submitting the amended research project entitled "Evaluation of *in vitro* effects of novel Aurigene CDK7 inhibitors on primary patient-derived AML blasts and determination of anti-tumor activity in patient-derived AML xenograft models" to TMC-ACTREC Institutional Ethics Committee for approval.

ase let us know if anything else is required.

Sincerely Yours'

Navih Khattry

Principal Investigator

nclosed

Ammendment form Summary of changes

Received by Shull 6

5OP 03/V4 Effective Date: 01/04/2016



IEC, TMC

Revised Budget for the Proposed Study

1. Source of funding	Aurigene				
Items	1st Year	2 nd Year	3 rd Year Total		
2. Salaries-personnel (Numbers) One		2 Teal	3 Year	Total	
1) Senior Research Fellow @28000 consolidated with 10% increment .	336000	369600	406560	1112160	
2) Clinical Trial coordinator @18000 consolidated with 10% increment	216000	237600	261360	714960	
1. Equipment and Hardware-					
1. Drugs and Consumables				40 150 9%	
-RealTime-Glo MT Cell Viability Assay	<u>(</u>				
(promega)	69329			69329	
RNA extraction kits (3) and cDNA synthesis (5) kits (Qiagen)	150000	_	*	150000	
Primers and probes or biomarkers analysis by RT-RQ PCR	250000		<u>.</u>	250000	
Reagents for cell culture	150000	100		150000	
drugs (Arsenic, retinoic acid, cytarabine, aunorubicin, etoposide)	60000	-	-	150000	
Clinical Investigations	20000	-		20000	
Hospitalization	-				
Travel expenditure for investigators					

Name of PI: Dr. Navin Khattry	Signature:	Nac	Dat	e: 05/11/16
15. Grand Total	1531473	607200	667920	2806593
14. Estimated Professional charges for clinical services. (15% at the end of the study on actual applicable for pharma sponsored studies)	NA .			
(TMC, DAE, ICMR, DBT, DST, IAEA, WHO, IARC etc. funded project are exempted)				de Streni
13. TMC Service Charge (10% of total applicable for pharma sponsored studies))	255144			255144
12.Miscellaneous (<5% of budget)	25000	-	-	25000
11. Any other expenditures		-	-	
ii. any unforeseen, accidental trial related injury				
i. for investigators	erau			
10. Insurance		- 1		
). Honorarium to doctors/technicians	-			
3. Travel expenditure for trial subject and one attendant		-		
col exponsitions for investigations				



TATA MEMORIAL CENTRE **ADVANCED CENTRE FOR TREATMENT, RESEARCH & EDUCATION IN CANCER**

(Grant-in-Aid Institute under Department of Atomic Energy, Govt. of India) Kharghar, Navi Mumbai 410210

INVOICE

INVOICE NO.

BR170004

Invoice Date:

21/03/2017

Invoice To:

Dr Murli Ramachandra

Aurigene Discovery Technologies Limited

Hyedrabad 500049

Sr No.	Details	No of Samples	Unit Price	Total Cost Rs.
1	Evaluation of in virto effects of novel Aurigene CDK7 inhibitors o primary patient derived AML blasts	1	700000	700000

Amount Excluding Service Tax	700,000.00
Service Tax @ 14%	98,000.00
Swachh Bharat Cess @ 0.5%	3,500.00
Krishi Kalyan Cess @ 0.5%	3,500.00
TDS (deducted at source)	70,000.00
Total Amount	735,000.00

Rupees Seven Hundred Thirty-Five Thousand

Total Amount Payable:

735,000.00

Tata Memorial Centre PAN

AAATT3620R

TMC-ACTREC Service Tax Registration No.

AAATT3620RSD003

Payment Terms: Within 7 days from the date of Invoice by way of cheque/demand draft drawn in favour of "Tata Memorial Centre - ACTREC" or can be directly credited in to our current account number as per details given below:

Name of the Account : Tata Memorial Centre - ACTREC

Name of the Bank

: Central Bank of India, ACTREC Branch, Kharghar, Navi Mumbai.

Current Account Number: 1797305746

RTGS/IFSC Code : CBIN0284047 9 - digit MICR Code : 400016114

Signature of the In-charge

For Tata Memoria Centre - ACTREC

Authorized Signatory

Note:

Tata Memorial Centre is exempted from deduction of TDS vide ITO Order No. 197/AAATT3620R/2016;17,71 / P. KAMALA उपलेखा नियंत्रक। Dy. Controller of Accounts dated 19/05/2016.

This is Computer Generated Document, Signature is not required.

टा. स्मा. के, अंक्ट्रेक खारवर I TMC ACTREC, Kharghar

नदी मुंबई -8१० २९० / Navi Mumbai - 410 210.



22 Mar 2017 Advice sending date:

Advice reference no: G32286333606

Page: 1/1 Payment Advice

Recipient's name and contact information:

mangayamma_g

mangayamma_g@aurigene.com

Transaction type: Priority payment Sub payment type: Core Payment

TATA MEMORIAL CENTRE ACTREC INR735,000.00 Beneficiary's name: Debit amount: Beneficiary's bank: CENTRAL BANK OF INDIA Remittance amount: INR735,000.00

KHARGHAR NAVI MUMBAI 410210 DIST RA Handling fee

IGARH

of remitting bank: Collect from Remitter

Beneficiary's account: 17973***** Value date: 22 Mar 2017

AURIGENE DISCOVERY TECH LTD (Part of the account number is shown Remitter's name: as ***** for security reasons.) HK and Shanghai Banking Corp Ltd Remitting bank:

Customer reference: 406029 Instruction reference: 900107MOPTPR Other reference: HSBCN17081064619

Remitter to beneficiary information:

InvNo	InvDate	Amount	TDS	NetAmount	Remarks
BR170004	21/03/17	735000		735000	

Important notes:
This Advice is issued at the request of our customer. It purports to set out certain details of the transaction that our Bank was instructed to effect. This is NOT a confirmation that the transaction has been or will be effected. You should conduct your own verification and confirmation regarding the information set out in this Advice including, without limitation, the status of the transaction mentioned in it. This Advice is for your reference only and is not to be relied upon by you or any one for any purpose. We have not verified the content of this Advice and bear no responsibility therefor. Where this Advice is sent by facsimile or over the internet, you should take note that communication by facsimile or over the internet may be interrupted, delayed or fail. In particular, e-mail messages sent via the internet cannot be guaranteed to be secure, error or virus-free as information could be intercepted, corrupted, lost, arrive late or contain viruses. The Bank shall bear no liability whatsoever for any direct, indirect or consequential loss arising out of this Advice being sent by facsimile or over the internet whether caused by the Bank or other third parties. The information contained in this Advice is confidential. It may also be legally privileged. If you are not the addressee you may not copy, forward, disclose or use any part of it.

No. BT/PR2372/AGR/36/696/2011

GOVERNMENT OF INDIA MINISTRY OF SCIENCE & TECHNOLOGY DEPARTMENT OF BIOTECHNOLOGY

Block 2, (6-8th Floors) CGO Complex, Lodhi Road, New Delhi- 110 003 Date 3/8/2016

RELEASE ORDER

In continuation of this Department's sanction order of even number dated Jun 04, 2013 sanction President is hereby assessment's sanction order of even number dated Jun 04, 2013 sanction order. of the President is hereby accorded, under Rule18 of the Delegation of Financial Powers Rule, 1978, for the release of Rs. 1200707 for the release of Rs. 1390722.00 (Rupees Thirteen Lakhs Ninety Thousand Seven Hundred and Twenty Two Only) being the the transfer of the Delegation of Financial Powers Rule; and Twenty Two Only) being the thirteen takks Ninety Thousand Seven Hundred and Twenty Two Only) being the transfer of the Delegation of Financial Powers Rule; and Twenty Two Only) being the transfer of the Delegation of Financial Powers Rule; and Twenty Two Only) being the transfer of the Delegation of Financial Powers Rule; and Twenty Two Only) being the transfer of the Delegation of Financial Powers Rule; and Twenty Two Only) being the transfer of the Delegation of Financial Powers Rule; and Twenty Two Only) being the transfer of the Delegation of Financial Powers Rule; and Twenty Two Only) being the transfer of the Delegation of Financial Powers Rule; and Twenty Two Only) being the transfer of the Delegation of Financial Powers Rule; and Twenty Two Only) being the transfer of the Delegation of Financial Powers Rule; and Twenty Two Only) being the transfer of the Delegation of Financial Powers Rule; and Twenty Two Only) being the transfer of the Delegation of Financial Powers Rule; and Twenty Two Only) being the transfer of the Delegation of Financial Powers Rule; and Twenty Two Only) being the transfer of the Twenty Two Only (Twenty Two Only) being the transfer of the Twenty Two Only (Twenty Two Only (Twe Twenty Two Only) being the third year release for the project entitled "Genome-wide RNAi screen with human pooled the third year release for the project entitled "Genome squamous cell with human pooled tyrosine kinase shRNA libraries in head and neck squamous cell carcinoma (HNSCC) carcinoma (HNSCC) cell lines", being implemented by

Dr Amit Dutt Advanced Centre For Treatment Research & Education In Cancer, Kharghar, Navi Mumbai, Mumbai, Mumbai, Mumbai, 410310 Mumbai, Mumbai - 410210, Maharashtra

The detailed break-up is as given

SNo	Institute Name	is as given	below:		30			Total Release
	- Name	Recurring					Amount (Rs)	
						Others	Overhead	
-		Manpower	Consumable	Travel	Contingency	Others		
	Advanced Centre For Treatment Research & Education In Cancer	78000.00	1262502.00	0.00	3345.00	0.00	46875.00	1390722.00
	Interest of Rs. 5	3,125/- is	l deducted fro	m overh	ead.			

2. The amount of Rs. 1390722.00 /-(Rupees Thirteen Lakhs Ninety Thousand Seven Hundred and Twenty Two Only) will be drawn by the Drawing & Disbursing Officer, DBT, from the Pay & Accounts Officer, DBT, and disbursed through RTGS as per following details:

The Director, Advanced Centre For Treatment Research & Education In Cancer, KHARGHAR, Mumbai - 410210 Maharashtra

Bank Name

Central Bank of India

Branch Name Kharghar Branch

A/c No.

1797305746

IFSC Code

CBI0284047

MICR Code 400016089

3. The expenditure involved is debitable to:

Demand No. 79	Department of Biotechnology	
Other Scientific Research 2016-2017		
3425.60	Others (Sub Major Head)	
3425.60.200	Assistance to other Scientific Bodies (Minor Head)	
3425.60.200.29	Biotechnology Research and Development	
3425.60.200.29.17	Assistance for Research and Development	
3425.60.200.29.17.31	Grants-in-aid General	

FILE NO. EMR/2015/001591

SCIENCE & ENGINEERING RESEARCH BOARD(SERB)

(a statutory body of the Department of Science & Technology, government of India)

5 & 5A, Lower Ground Floor Vasant Square Mall Plot No. A, Community Centre Sector-B, Pocket-5, Vasant Kunj New Delhi-110070

Dated: 21-Aug-2018

ORDER

Subject: Research project entitled "Analysis of HPV, EGFR and Hypoxia markers and their association with outcome in subjects with locally advanced Squamous cell carcinoma of head and neck." under the guidance of Dr. Manoj B Mahimkar, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre (Tata Memorial Hospital), Dr. E Borges Road, Parel, Mumbai, Mumbai City, Maharashtra-400012.

- 1. This is in continuation of SERB's sanction order No. "EMR/2015/001591" dated "25 May, 2016" of Science and Engineering Research Board (SERB).
- 2. Sanction of the competent authority is hereby accorded to the payment of a sum of Rs. 1000000/- (Rupees Ten Lakh only) under 'Grants-in-aid General' to Director, ACTREC TMC, Tata Memorial Centre (Tata Memorial Hospital), Dr. E Borges Road, Parel, Mumbai being the 3rd grant for the financial year 2018-2019 for implementation of the above said project.
- 3. Sanction of the competent authority is also accorded to the carry forward of unspent balance of Rs. 310308/- (Rupees Three Lakh Ten Thousand Three Hundred and Eight only) (Recurring Rs. 310308 and Non-Recurring Rs. 0) to Tata Memorial Centre (Tata Memorial Hospital), Dr. E Borges Road, Parel, Mumbai from FY 2017-2018 to FY 2018-2019 for the same purpose for which it was sanctioned
- 4. Sanction of the grant is subject to the conditions as detailed in Terms & Conditions available at the website (www.serb.gov.in).
- 5. It is certified that provision of GFR 212 relating to Utilization Certificates (Ucs) for the funds released under the grant have been satisfied and the UC/s is/are enclosed herewith.
- 6. The expenditure involved is debitable to Fund for Science & Engineering Research (FSER) This release is being made under Core Research Grant. (PAC Health Sciences) (GEN)
- 7. The Sanction has been issued to Tata Memorial Centre (Tata Memorial Hospital), Dr. E Borges Road, Parel, Mumbai with the approval of the competent authority under delegated powers on 14 August, 2018 and vide Diary No. SERB/F/5832/2018-2019 dated 21 August, 2018

8. The release amount of **Rs. 1000000/-** (Rupees Ten Lakh only) will be drawn by the Under Secretary of the SERB and will be disbursed by means of BTGS transaction as per their Bank details given below:

	ans of troot transaction as per their bank actains given below.
Account Name	TATA MEMORIAL CENTRE - ACTREC
Account Number	1797305746
Bank Name & Branch	CENTRAL BANK OF INDIA KHARGHAR BRANCH, ACTREC CAMPUS, Sector 22, Kharghar Navi Mumbai, 410210 Maharashtra
IFSC/RTGS Code	CBIN0284047
Email id of A/C Holder	pkamala@actrec.gov.in
Email id of PI	mmahimkar@actrec gov in

- 9. The institute will maintain separate audited accounts for the project. A part or whole of the grant must be kept in an interest earning bank account which is to be reported to SERB. The interest thus earned will be treated as credit to the institute to be adjusted towards further installment of the grant.
- 10. As per rule 211 of GFR the accounts of Grantee Institution shall be open to inspection by the sanctioning authority / audit whenever the institute is called upon to do so.
- 11. The institute will furnish to the SERB, Utilization certificate(separate for Recurring & Non-Recurring) and an audited statement of accounts pertaining to the grant immediately after the end of each financial year.
- 12. After completion of the project unspent balance if any should be returned as Demand Draft drawn in favour of "Fund for Science and Engineering Research" payable at New Delhi.
- 13. The organization/institute/university should ensure that the technical support/financial assistance provided to them by the Science & Engineering Research Board, a statutory body of the Department of Science & Technology (DST),

Government of India should invariably be highlighted/acknowledged in their media releases as well as in bold letters in the opening paragraphs of their Annual Report.

14. In addition, the investigator/host institute must also acknowledge the support provided to them in all publications, patents and any other output emanating out of the project/program funded by the Science & Engineering Research Board, a statutory body of Department of Science & Technology (DST), Government of India.

Balachandar Venkatesan Scientist I

ms_hs@serbonline.in

To, Under Secretary SERB, New Delhi

Copy forwarded for information and necessary action to: -

1.	The Principal Director of Audit, A.G.C.R.Building, IIIrd Floor I.P. Estate, Delhi-110002
2.	Sanction Folder, SERB , New Delhi.
3.	File Copy
4.	Dr. Manoj B Mahimkar Advanced Centre for Treatment, Research and Education in Cancer Tata Memorial Centre (Tata Memorial Hospital), Dr. E Borges Road, Parel, Mumbai, Mumbai City, Maharashtra-400012 Email: mmahimkar@actrec.gov.in Mobile: 919820665644
5.	Director, ACTREC - TMC, Tata Memorial Centre (Tata Memorial Hospital), Dr. E Borges Road, Parel , Mumbai

(Dr. Balachandar Venkatesan) Scientist E

ms_hs@serbonline.in



TATA MEMORIAL CENTRE टाटा स्मारक केंद्र

ADVANCED CENTRE FOR TREATMENT RESEARCH & EDUCATION IN CANCER

कैंसर उपचार, अनुसंधान एवं शिक्षा का प्रगत केंद्र A GRANT-IN-AID INSTITUTE UNDER DEPARTMENT OF ATOMIC ENERGY, GOVT. OF INDIA प.ऊ.वि. भारत सरकार का एक सहायता अनुदान प्राप्त संस्थान INSTITUTIONAL ETHICS COMMITTEE-III

DCGI Reg. No.: IEC III :- ECR/149/Inst/MH/2013

IEC Outward No.: 292 /20 15



Date: 06.07.2015

To Dr. Vivek Bhat Principal Investigator ACTREC

Ref: Final Approval of project # 148

Dear Dr. Bhat,

Institutional Ethics Committee reviewed and discussed your application dated 05.08.2014 to conduct the research study entitled "A prospective observational study to evaluate tumor associated substance hydroxyl pheylalanine(tyrosine) in the urine of cancer patients" during the 44th TMC-ACTREC IEC meeting held on 19.06.2015 at 10 a.m. in the Boardroom, 3rd Floor, Paymaster Shodika at ACTREC.

The following members of the TMC-ACTREC IEC were present:

SI. No.	Name & Position	Affiliation	Gender	Expertise	
1.	Dr. Rita Mulherkar Chairperson	Kharghar, Navi Mumbai.	Female	Basic Scientist	
2.			Male	Radiation Oncologist	
3.	3. Dr. Vikram Gota Member Associate Professor, Dept of Clinical Pharmacology, ACTREC		Male	Clinical Pharmacologist (Basic Medical Scientist)	
4.	Dr. B.B. Singh Member	B. Singh Advocate, Mumbai High Court		Legal Expert	
5.	Dr. Bharat Rekhi Member	Professor, Dept of Pathology, Tata Memorial Hospital, Mumbai.	Male	Pathologist (Basic Medical Scientist)	
6.	Mrs. Lakshmi, R. Member	Co-ordinator, Sanjeevani life beyond cancer, Mumbai.	Female	Social Scientist	
7.	Mrs. Deepa Ramani Member	Ex-play group teacher, store and purchase in-charge, Kharghar.	Female	Layperson	
8.	Dr. Tejpal Gupta Member	Associate Professor, Dept. of Radiation Oncology, ACTREC	Male	Radiation Oncologist	
9.	Dr. Navin Khattry Member	Professor, Dept of Medical Oncology, ACTREC	Male	Medical Oncologist	
10	Dr. Kumar Prabhash Member	Professor Dept of Medical Oncology, Tata Memorial Hospital	Male	Medical Oncologist	
11	Dr. Prasanna V Member	Scientific Officer 'F', ACTREC	Female	Basic Scientist	

IEC Office TMC-IEC III Room No. 128, First Floor, Paymaster Shodhika, Kharghar, Navi Mumbai - 410 210, India Phone/Fax No.: +91-22-2740 5154

Final Approval_148_2015

E-mail : irb@actrec.gov.in Website : www.actrec.gov.in

आय ई सी कार्यालय टीएमसी-आईसी-III कुम नं. १२८, १ला माला, पेमास्टर शोधीका, खारघर, नवी मुंबई - ४१० २१० भारत दुरभाष/फैक्स: ०२२-२७४० ५१५४

12	Dr. Manoj Mahimkar Member	Scientific Officer 'F', ACTREC	Male	Basic Scientist
13	Mrs. Sadhana Kannan Member	Scientific Officer 'E' Data Manager, ACTREC	Female	Bio-statistician

The following documents were reviewed:

- 1. Project submission form
- 2. Proposal
- 3. ICF in English, Hindi and Marathi version 1 dated 04.08.2014
- 4. Case Report Form
- 5. Clinical Trial Agreement
- 6. CVs
- Reply to IEC dated 10.12.2014
- 8. Amendment reporting form
- 9. Revised Project submission form
- 10. Revised ICFs in English, Hindi & Marathi version 1.1 dated 04.12.2014
- 11. Reply to IEC dated 13.03.2015
- 12. Amendment Reporting Form
- 13. Revised IEC Form version 1.2 dated 05.03.2015
- 14. Revised Protocol version 1.2 dated 05.03.2015
- 15. Covering letter dated 30.05.2015
- 16. Amendment Reporting form
- 17. Revised IEC Form
- 18. Revised Study Protocol version 1.3 dated 30.05.2015(Approved)
- 19. Revised ICFs in English, Hindi & Marathi version 1.2 dated 30.05.2015(approved version)

Decision: The study is approved in the present form. IEC approved the continuation of the study till 06.07.2016 It is mandatory to submit study status report annually. You are requested to submit annual status report on or before 06.07.2016.

Following points must be noted:

- 1. IEC has approved recruitment 200 Subjects on this study.
- 2. IEC should be informed of the yearly progress of the study by the PI. Failure to submit the continuing review application/annual status report may result in withdrawal of IEC approval.
- 3. IEC has approved the conduct of the study at Tata Memorial Centre Mumbai.
- 4. Principal Investigator and study team should be GCP trained
- 5. PI and other investigators should notify initiation of the study.
- 6. PI and other investigators should co-operate fully with data and safety monitoring Sub-committee (DSMSC), who will monitor the study from time to time.
- 7. The decision was arrived at through consensus/unanimous or majority opinion amongst the voting members of IEC. Member(s) of the committee who is/are listed as investigator(s) on a research proposal opted out from all deliberations on the proposal and did not participate in decision making. Neither PI nor any of proposed study team members participated during the decision making of the IEC. IEC members with any conflict of

- interest opted out from all deliberations on the proposal and did not participate in decision making.
- 8. At the time of PI's retirement/intention to leave the institute, study responsibility should be transferred to colleague after obtaining clearance from HOD and/or convener of the PI's DMG and IEC. Status report, including accounts details should be submitted to HOD and extramural sponsors.
- 9. The IEC functions in accordance with its SOP and is compliant with the Schedule Y (Drugs & Cosmetic Act 1940), ICMR guidelines and ICHGCP
- 10. In the events of any protocol amendments, IEC must be informed and the amendments should be highlighted in clear terms as follows:
 - a) The exact alteration/amendment should be specified and indicated where the amendment occurred in the original project. (Page no. Clause no. etc.)
 - b) Alteration in the budgetary status should be clearly indicated and the revised budget form should be submitted
 - c) If the amendments require a change in the consent form, the copy of revised Consent Form should be submitted to Institutional Ethics Committee for approval.
 - d) If the amendment demands a re-look at the toxicity or side effects to patients, the same should be documented.
 - e) If there are any amendments in the study design, these must be incorporated in the protocol, and other study documents. These revised documents should be submitted for approval of the SRC and IEC, only then can they be implemented.
 - f) Approval for amendment changes must be obtained prior to implementation of changes. Without including all the above points, the amendment is unlikely to be approved by the IEC.
 - g) Any deviation/violation/waiver in the protocol must be informed to the IEC.

Thanking you,

Yours sincerely,

Dr Vedang Murthy Member Secretary

IEC III

Thub and p & le

TO,

professor RA Badwe,

Director Tata Memorial Centre



Subject: Application for seed grant under the western India research consortium for collaborative studies with IIT-B

Dear Sir,

I would like to submit a collaborative research proposal with IIT-B (Rinti Banerjee- Biomedical engineering group) for the above seed grant. This research proposal aims at evaluating a mucosal nanoparticle-in-gel system for regional delivery of radio-sensitizing agents in an oral cancer xenograft model. We had initially done a collaborative research project involving paclitaxel alone earlier and the results of the study has been submitted to a peer reviewed nanomedicine journal. Now we want to take this work forward by using dual drug combination in a liposomal gel formulation for loco-regional drug delivery. This study will be initially a proof of concept study. Once we get the desirable results we would like to scale it up and do phase-1 studies in humans.

I am herewith attaching the project proposal for your perusal and suggestions

Original Copy Sent to TMH

Dt. 12 22/02/16

At the same time I request you to help us by funding the project with the seed grant for implementing the collaborative project.

Thanking you!

Yours sincerely

Jayant S Goda

Ms. Asur check wedit

Lower for the form of the form

To the Director

DATE:24/1/16

ACTREC Kharghar

Through Accounts officer(P Kamla)

Sub: creation of account at ACTREC for depositing the grant money for the implementation of the

"Titled: Evaluation of mucosal nanoparticle-in-gel system for regional delivery of radiosensitizing agents in an oral cancer xenograft model"

Dear Madam,

I would like to bring to your notice that my project entitled "Evaluation of mucosal nanoparticle-in-gel system for regional delivery of radiosensitizing agents in an oral cancer xenograft model" has been approved on 8th dec 2015 by the IAEC proposal no 201/2015.

I also have an approved WIHC grant of 10,00,000(INR ten lakhs) approved by Director TMC(a copy of which I am submitting along with this letter.

I would appreciate if you could direct the accounts department to create an account for the approved grant so that the grant money can be deposited in the account for the implementation of the project.

Thanking you!

Yours sincerely

Associate Professor and PI of the project.

Enclosures: 1. Approval of the project

2 Document regarding approval of the grant

3. PROJECT proposal

Director may please otherone obening of new ledger

Code prabore project Carabo 2/2/16

Disector

ACTREC.

S.N. 7223 Date 4/R/16

Ms. Hasshele - B. take newcode

GOVERNMENT OF INDIA MINISTRY FOR SCIENCE & TECHNOLOGY DEPARTMENT OF BIOTECHNOLOGY

RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY
THIRUVANANTHAPURAM 695014
An Autonomous National Institute for Discovery, Innovation & Translation in
Biotechnology and Disease Biology

6242-P61/RGCB/PMD/DBT/ARMR/2015

September 11,2015

RELEASE ORDER

In Continuation of this Department's sanction order of even number dated July 29,2015, sanction of the resident is hereby accorded, under Rule 18 of the Delegation of Financial Powers Rule,1978, for the release of Rs. 7,16,210 (Rupees Seven Lakhs Sixteen Thousand Two Hundred and Ten Only) being the first year release for the project "Targeting the life-threatening complications (HVOD & GVHD) associated with allogeneic Haematopoietic Stem Cell Transplantation (allo HSCT), being GVHD) associated with allogeneic Haematopoietic Stem Cell Transplantation (allo HSCT), being GVHD) associated with allogeneic Haematopoietic Stem Cell Transplantation (allo HSCT), being GVHD) associated with allogeneic Haematopoietic Stem Cell Transplantation (allo HSCT), being GVHD, associated with allogeneic Haematopoietic Stem Cell Transplantation (allo HSCT), being GVHD, associated with allogeneic Haematopoietic Stem Cell Transplantation (allo HSCT), being GVHD, associated with allogeneic Haematopoietic Stem Cell Transplantation (allo HSCT), being GVHD, associated with allogeneic Haematopoietic Stem Cell Transplantation (allo HSCT), being GVHD, associated with allogeneic Haematopoietic Stem Cell Transplantation (allo HSCT), being GVHD, associated with allogeneic Haematopoietic Stem Cell Transplantation (allo HSCT), being GVHD, associated with allogeneic Haematopoietic Stem Cell Transplantation (allo HSCT), being GVHD, associated with allogeneic Haematopoietic Stem Cell Transplantation (allo HSCT), being GVHD, associated with allogeneic Haematopoietic Stem Cell Transplantation (allo HSCT), being GVHD, associated with allogeneic Haematopoietic Stem Cell Transplantation (allo HSCT), being GVHD, associated with allogeneic Haematopoietic Stem Cell Transplantation (allo HSCT), being GVHD, associated with allogeneic Haematopoietic Stem Cell Transplantation (allo HSCT), being GVHD, associated with allogeneic Haematopoietic Stem Cell Transplantation (allo HSCT), being GVHD, associated with allogeneic Haematopoietic Stem Cell Transplantation (a

210. The amount of **Rs. 7,16,210 (Rupees Seven Lakhs Sixteen Thousand Two Hundred and Ten Only)** will be drawn by the Drawing & Disbursing Officer, Rajiv Gandhi Center for Biotechnology (RGCB), from DBT and disbursed through RTGS/Demand Draft as per following details:

Tata Memorial Centre (TMC), Advanced Centre for Treatment Research & Education in Cancer (ACTREC)

Bank Name

: Central Bank of India

Branch Name

: Kharghar, Navi-Mumbai : 1797305746

A/c No. IFSC Code

2.

CBIN0284047

MICR Code

Advanced Centre for Treatment Research & Education in Cancer (ACTREC), will submit audited Utilization Certificates and statements of expenditure in respect of the above-mentioned amount. The Accounts of grantee institution shall be open to inspection by the sanctioning authority/audit

The Accounts of grantee institution shall be open to inspection of the canadamy when ever the Institute is called upon to do so by the sanctioning authority.

No International Travel will be undertaken from the sanctioned project grant unless specified otherwise

No International Traver will be undertaken from the database project grant unless specified which was 6.

(a) In case the whole or a part of the amount of grant-in-aid is being refunded, an interest at the rate of ten Percent annum thereon shall be recovered.(b) Non-Recurring grant shall be utilized within 18 months of their release. The other terms and conditions governing the financial sanction will remain unaltered

7. This issues under powers delegated to the Rajiv Gandhi Centre for Biotechnology, vide letter No.DO.No.BT/Med/Pilot Project Cancer/2014 dated 26.06.2015 and Department of Biotechnology with the concurrence of IFD, DBT.

8. This Sanction order has been noted at serial no. 61 in the Register of Grants.

Chief Project Officer

Pilot Project Grants, Program for Young Investigators in Cancer Biology

Rajiv Gandhi Centre for Biotechnology

File No. BT/513/NE/TBP/2013 GOVERNMENT OF INDIA MINISTRY OF SCIENCE & TECHNOLOGY DEPARTMENT OF BIOTECHNOLOGY (NER DIVISION) *******

Block-2, 7th Floor, CGO Complex, Lodhi Road New Delhi-110003 Dated: 16 / 4 / 2014

ORDER

Sanction of the President is hereby accorded under Rule 18 of the Delegation of Financial Powers Rules, 1978 for the implementation of the project under 'DBT's Twinning programme for the NE' titled "Functional characterization of clinically significant mutations inh-BRCA1 gene among the Mizoram population." by Dr. Muthukumaran, R., Mizoram University, Tanhril, Aizawl, Dr. Jeremy L. Pautu, Mizoram State Cancer Institute, Zemabawk, Aizawl and Dr. Ashok K Varma, Tata Memorial Centre, Advanced Centre for treatment, Research and Education in Cancer, Kharghar, Navi Mumbai at a total cost of ₹ 61.64 lakhs (Rupees Sixty One lakhs and Sixty Four Thousand only) for a period of three years, on the terms and conditions detailed as under:

2.0 The Project:

2.1 Project Title: Functional characterization of clinically significant mutations inh-BRCA1 gene among the Mizoram population.

2.2 Project Investigators

2.2.1 Principal Investigator: (Parent Institute)

Dr. Muthukumaran, R.
Associate Professor,
Dept. of Chemistry,
Mizoram University, Tanhril,
Aizawl, Mizoram-796004

2.2.2 Co- Investigator: I (Parent Institute)

Professor N. Senthil Kumar Professor, Dept. of Biotechnology, Mizoram University, Tanhril, Aizawl, Mizoram-796004

2.2.3 Co- Investigator: II (Parent Institute)

Dr. G. GuruSubramanian, Associate Professor Dept. of Zoology, Mizoram University, Tanhril, Aizawl, Mizoram-796004

2.2.4 Principal Investigator: (Collaborating Institute-I)

Dr. Jeremy L. Pautu Medical Oncologist, Dept. of Oncology, Mizoram State Cancer Institute, Zemabawk, Aizawl-796017



2.2.5 Co-Investigator:

Dr. Doris Lallawmzuali,

(Collaborating Institute)

Pathologist

Dept. of Pathology,

Mizoram State Cancer Institute, Zemabawk, Aizawl-796017

2.2.6 Principal Investigator:

Dr. Ashok K Varma

(Collaborating Institute-II)

Scientist - F,

Dept. of Advanced Centre for Treatment Research and

Education in Cancer,

Tata Memorial Centre, ACTREC, Kharghar,

Navi Mumbai - 410210

Co-Investigator: 2.2.7

Nikhil Gadewal,

Scientist D,

(Collaborating Institute)

Dept. of Bioinformatics Centre,

Tata Memorial Centre, ACTREC, Kharghar,

Navi Mumbai - 410210

2.3 Objectives:

• Genotyping for the identification of genetic abnormalities of BRCA1 in familial Breast malignancies for diagnosis.

2.4 Time Schedule:

The duration of the project is three years from the date of issue of sanction order.

2.5 Equipment Details:

2.5.1 Mizoram University, Tanhril, Aizawl

Sl. No.	Item	Grant Recommended (in Lakhs)
1.	PCR Machine	2.20
2.	Micropipette set	3.28
3.	Balance (± 0.001 g)	0.42
4.	pH Meter	0.37
denote a	Total	4.07

2.5.2 Mizoram State Cancer Institute, Zemabawk, Aizawl

Sl. No.	Item	Grant Recommended (in Lakhs)
1.	Minispin centrifuge	0.50
2.	Balance (± 0.01 g)	0.30
3.	Micropipette set	0.70
4.	Deep freezer (-20°C)	0.75
5.	Digital vortex mixer (2)	0.06
6.	Magnetic stirrer (2)	0.06
	Total	2.37

2.5.2 Tata Memorial Centre, Advanced Centre for Treatment, Research and Education in Cancer, Kharghar, Navi Mumbai

Sl. No.	Item	Grant Recommended (in Lakhs)		
1.	Centrifuge	3.00		
	Total	3.00		

2.6 Manpower:

Fellowship Conditions:

JRF emoluments shall be ₹ 16,000/- + HRA for the 1st two years and ₹ 18,000/- + HRA for the 3rd year for SRF and applicable, only if JRF/SRF is NET/GATE/BET/BINC SLET/Professional course qualified, otherwise it shall be ₹ 12,000/- + HRA for the 1st two years for JRF and ₹ 14,000/- + HRA for the 3rd year for SRF.

2.6.1 Mizoram University, Tanhril, Aizawl

				(₹ in la		
S. No.	Position (No.)	Emolument	1st Year	2 nd Year	3rd Year	Total
1.	JRF/SRF(2)	JRF @ ₹ 16,000/- + 10 % HRA for the 1 st & 2 nd yr SRF @ ₹ 18,000/- + 10 % HRA for 3 rd yr	4.22	4.22	4.76	13.20
	24	Total	4.22	4.22	4.76	13.20

2.6.2 Mizoram State Cancer Institute, Zemabawk, Aizawl

S. No.	Position (No.)	Emolument	1st Year	2 nd Year	(₹ in la	Total
1.	Lab Attendant	@₹5,000/-	0.60	0.60	0.60	1.80
		Total	0.60	0.60	0.60	1.80

2.6.3 Tata Memorial Centre, Advanced Centre for Treatment, Research and Education in Cancer, Kharghar, Navi Mumbai

	(₹ in						in lakhs)	
S No.	Position (No)	Consolidated Emolument	1st	Year	2nd	Year	3rd year	Total
1.	JRF/SRF (1)	JRF @ ₹ 16,000/- + 30 % HRA for the 1 st & 2 nd yr SRF @ ₹ 18,000/- + 30 % HRA for 3 rd yr		2.50		2.50	2.80	7.80
		Total	2	2.50	2	.50	2.80	7.80

of

2.7 Budget Estimate:

The total cost of the project is ₹ 61.64 lakhs (Rupees Sixty One lakhs and Sixty Four thousand only) as per budget summary given below:

2.7.1 Mizoram University, Tanhril, Aizawl

(₹ in lakhs)

			(makis)		
Heads	1st Year	2 nd Year	3 rd Year	Total	
I. Non-Recurring (Equipment's and accessories)	4.07	0.00	0.00	4.07	
Sub Total- I	4.07	0.00	0.00	4.07	
II. Recurring			tall gioss		
1. Manpower	4.22	4.22	4.76	13.20	
2. Consumables	3.50	3.00	2.50	9.00	
3.Travel	0.50	0.50	0.50	1.50	
4. Contingency	0.50	0.30	0.20	1.00	
5.Overhead charges	0.40	0.30	0.30	1.00	
Sub Total- II (1-5)	9.12	8.32	8.26	25.70	
GRAND TOTAL (I+II)	13.19	8.32	8.26	29.77	

2.7.2 Mizoram State Cancer Institute, Zemabawk, Aizawl

(₹ in lakhs)

1st Year	2 nd Year	3 rd Year	Total	
2.37	0.00	0.00	2.37	
2.37	0.00	0.00	2.37	
0.60	0.60	0.60	1.80	
0.80	0.60	0.40	1.80	
0.50	0.50	0.50	1.50	
0.20	0.15	0.15	0.50	
0.20	0.15	0.15	0.50	
2.30	2.00	1.80	6.10	
4.67	2.00	1.80	8.47	
	2.37 2.37 0.60 0.80 0.50 0.20 0.20 2.30	2.37 0.00 2.37 0.00 0.60 0.60 0.80 0.60 0.50 0.50 0.20 0.15 0.20 0.15 2.30 2.00	2.37 0.00 0.00 2.37 0.00 0.00 0.60 0.60 0.60 0.80 0.60 0.40 0.50 0.50 0.50 0.20 0.15 0.15 0.20 0.15 0.15 2.30 2.00 1.80	



2.7.3 Tata Memorial Centre, Advanced Centre for Treatment, Research and Education in Cancer, Kharghar, Navi Mumbai (₹ in lakhs)

			(\ In takns)		
Heads	1st Year	2nd Year	3rd Year	Total 3.00	
I. Non-Recurring (Equipment's and accessories)	3.00	0.00	0.00		
Sub Total- I	3.00	0.00	0.00	3.00	
II. Recurring					
1. Manpower	2.50	2.50	2.80	7.80	
2. Consumables	4.00	3.00	3.00	10.00	
3.Travel	0.30	0.30	0.40	1.00	
4. Contingency	0.50	0.30	0.20	1.00	
5.Overhead charges	0.25	0.20	0.15	0.60	
Sub Total- II (1-5)	7.55	6.30	6.55	20.40	
GRAND TOTAL (I+II)	10.55	6.30	6.55	23.40	

- (i) Grand total for 3 years (29.77 + 8.47 + 23.40) = ₹ 61.64 lakhs
- (ii) Total for 1st year release (13.19 + 4.67 + 10.55) = ₹ 28.41 lakhs

2.8 Other Terms & Conditions:

- 2.8.1 The other terms and conditions governing this sanction are attached at Annexure-I.
- 2.8.2 A Memorandum of Agreement (MoA) will be signed between the Department of Biotechnology and the grantee institute on a ₹ 100/- stamp paper in the format given at Annexure II and the subsequent releases will be made only after signing of MoA by the grantee institute and its acceptance by DBT. All pages need to be signed by the PI and the forwarding authority and the MoA returned to DBT within 30 days of issue of this letter.
- 2.8.3 The Non-recurring items must be procured and installed within 6 month period from the date of sanction.
- 2.8.4 In case the amount of grant-in-aid is refunded, the whole or a part amount of the grant, with an interest at 10% per annum there on shall be recovered.
- 2.8.5 No international travel will be undertaken from the sanctioned project grant unless specified otherwise.
- 2.8.6 The Institute/Agency will keep the whole of the grant in a Bank Account earning interest, and the interest so earned should be reported to DBT in the Utilization Certificate and statement of Expenditure. The interest so earned will be treated as created to the institute / Agency and shall be adjusted towards further installment of the grant and or at the time of Final Settlement of Account.

2.9 Additional Terms & Conditions, specific for Twinning R&D program for NER:

- 2.9.1 Both NER & Rest of India (RoI), Institutions scientists should work together for the objectives stated in the sanction of the project and any deviation from this would attract closure of the project at any point of time.
- 2.9.2 In the project review meetings, both the PI's from NER & RoI Institutions should participate & make presentation.

5 of 6

- The outcomes of the project such as research papers, patents, copy rights etc. should be made 2.9.3 jointly.
- The NER Scientists are to be trained at the collaborating institute appropriately to empower the 2.9.4 NER Scientists.
- The project personal such as Research Associate, JRF/SRF, Research Assistant are also to be 2.9.5 trained at least once in the collaborating national institute.
- The collaborating institute scientist should visit NER institutions more frequently to guide NER scientists in design and conduct of experiments.
- This issues under the powers delegated to this Department and with the concurrence of IFD, DBT 2.10 vide their Dy No. 102/I.F.D/SAN/2628-2643/ 2013-14 Dated 02/09/2013.
- 2.10.1 This sanction order has been noted at Serial No...... in the Register of Grants.
- 2.10.2 The accounts of grantee institution shall be open to inspection by sanctioning auditory / audit.
- M/S Biotech Consortium India Ltd (BCIL), Anuvrat Bhawan, 210, Deen Dayal Upadhayay Marg, 3.0 New Delhi- 110002, is administrating the North Eastern Region Biotechnology Programme Management Cell (NER-BPMC) of the DBT. Vendali Panjali

(Dr. Vaishali Panjabi) Scientist 'C'

The Pay & Accounts Officer, Department of Biotechnology, New Delhi - 110003

Copy to:

- 1. The Principal Director of Audit (Scientific Department), AGCR Building, New Delhi 110 002.
- 2. Cash Section, DBT (For information only).
- 3. Sanction Folder.
- 4. IFD, DBT.
- 5. The Registrar, Mizoram University, Tanhril, Aizawl 796004, Mizoram
- 6. The Director, Mizoram State Cancer Institute, Zemabawk, Aizawl-796017
- The Director, Tata Memorial Centre, Advanced Centre for Treatment, Research and Education in Cancer, Kharghar, Navi Mumbai - 410210
- 8. The Vice-chancellor, Mizoram University, Tanhril, Aizawl 796004, Mizoram
- 9. Dr. Muthukumaran, R., Associate Professor, Dept. of Chemistry, Mizoram University, Tanhril, Aizawl, Mizoram-796004
- 10. Dr. Jeremy L. Pautu, Medical Oncologist, Dept. of Oncology, Mizoram State Cancer Institute, Aizawl-796017, Zemabawk
- 11. Dr. Ashok K Varma, Dept. of Advanced Centre for Treatment Research and Education in Cancer,. Tata Memorial Centre, Kharghar, Navi Mumbai - 410210
- 12. Concern file.
- 13. The Managing Director, Biotech Consortium India Limited, (NER-BPMC), 5th Floor, Anuvart Varslali Paryah Bhawan, 210, Deen Dayal Upadhyay Marg, New Delhi- 110002.

(Dr. Vaishali Panjabi) Scientist 'C'

Mumbai 400 001.

COPY

Tel: 66657465 Fax: 22826092

e-mail:

figuard@sdtatatrust.com

10th September 2014

Dr. Sanjay Gupta
Cancer Research Institute
Advanced Centre for Treatment Research
and Education in Cancer
Tata Memorial Centre
Kharghar
Navi Mumbai 410210.

Dear Dr. Gupta,

This has reference to your online application for the year 2014-15 for financial assistance for your institutional research project titled "HISTONE DEACETYLASE INHIBITOR AS A POTENTIAL SENSITIZER FOR CHEMOTHERAPEUTIC DRUGS FOR INCREASING THEIR THERAPEUTIC GAIN IN GASTRIC CANCER: A PRECLINICAL STUDY" to be carried out at the Advanced Centre for Treatment Research and Education in Cancer, Navi Mumbai.

Your research project was scrutinized by Members of our Indian Scientific Advisory Committee (ISAC), and you were, thereafter, invited to make a presentation before the ISAC at our July 19, 2014 interview meeting.

We are glad to inform you that on the recommendation of the Members of our Indian Scientific Advisory Committee, the Trustees have sanctioned a partial financial support of Rs.5,00,000/- per year, for your above 2-year research project. The grant will be disbursed in two equal instalments in the following manner:

YEAR	AMOUNT (Rs.)
2014-2015	5,00,000/-
2015-2016	5,00,000/-
Total:	10,00,000

Our cheque for Rs.5,00,000/- drawn in favour of the **DIRECTOR-ACTREC**, **TMC**, is enclosed, being the grant for the first year, with a request to kindly acknowledge receipt in due course.

1914114

IEC/1114/011

December 15, 2014

To, Dr. Sudhir Nair, Principal Investigator, TMH

Dear Dr. Nair.

It is our pleasure to inform you that your project no. 58 entitled "Development of a gene signature predicting cervical lymph node metastasis in tongue squamous cell carcinoma (GSP-TSCC)" has been sanctioned financial support which is as follows:

Financial year – 2014-2015
Funding Source – IM-ACTREC
Sanctioned amount- Rs.265,000.00 (Rupees two lacs sixty five thousand only)

The details of the fund sanctioned are as follows:

	Head	(2014-2015)
1.	Manpower	180,000.00
2.	Drugs/Consumables	45,000.00
3.	Other expenditures	40,000.00
	Total	265,000.00

^{*} The budget should be utilized only for the purpose for which it is sanctioned.

You are requested to submit the continuing review applications timely as per DSMSC guidelines. It is mandatory for Principal Investigators to submit the project progress report (not more than 3 pages) to TRAC (Ms. Rohini Hawaldar) on or before 28th September, 2015. The report should cover the points mentioned below:

- a. Start date of project
- b. Work completed till August 2015
- c. Work remaining
- d. Funds utilized and Balance
- e. Details of attempts made for funding from other agencies like DBT, ICMR etc.

- f. In case the Principal Investigator has been unable to generate funds he/she should make a written request for further financial support from the TMC for 2015-2016. Kindly submit the revised budget sheet with justification incase of any revision from original budget submitted.
- g. Any publication/presentation of the study (duly acknowledging the funding agency)

Thanking you,

Yours sincerely,

Panawaldar

Ms. Rohini Hawaldar, TRAC Administrator

CC:

Director, TMC
Director, TMH
Director, ACTREC
Deputy Director CRC, ACTREC
Director Academics
MS, TMH
HOD of PI
Secretary, IEC
CAO, TMC
JCA, TMC
OIC, DAE-CTC

LADY TATA MEMORIAL TRUST

Founded 1932 Bombay House, Homi Mody Street Mumbai 400 001.

> Tel: 66657465 Fax: 22826092

e-mail: fjguard@sdtatatrust.com

19th March 2014

Dr. Navin Khattry
Associate Professor &
BMT Programme Co-Ordinator
Department of Medical Oncology
Room No.247, Paymaster Shodhika
Cancer Research Institute
ACTREC, Tata Memorial Centre,
Kharghar, Navi Mumbai 410 208.

Dear Dr. Khattry,

This has reference to your application dated 23rd May 2011 for financial assistance for your institutional research project titled "EVALUATION OF VARIOUS MOLECULAR PROGNOSTIC MARKERS AND MINIMAL RESIDUAL DISEASE (MRD) TO POTENTIATE THERAPY FOR ACUTE MYELOID LEUKEMIA (AML) PATIENTS: A TWO-STEP MOLECULAR-CLINICAL INVESTIGATION" to be carried out at the Tata Memorial Centre, ACTREC, Navi Mumbai and our letter of 28th September 2011 sanctioning the grant together with the first instalment.

We are glad to inform you that on the scrutiny and recommendation of your second year research progress report by the Members of our Indian Scientific Advisory Committee, we release the third and final year grant of Rs.49,10,000/-, drawn in favour of **Director, ACTREC-TMC**, which is enclosed. Kindly acknowledge receipt in due course. The SAC Members, however, expect that in 2014-15 you will be able to complete the collection and analysis of 63 samples of the proposed 150.

A consolidated statement of expenditure, signed by an appropriate officer of your institution is to be furnished to the Trust on completion of your final year of the above research project.

You will send us the final Progress Report on your Project for the perusal of our Indian Scientific Advisory Committee.

With warm regards,

Yours sincerely

(F. J. Guard) Secretary

Encl.: Cheque for Rs.49,10,000/- drawn in favour of

Director, ACTREC-TMC

भारतीय आयुविज्ञान अनुसंधान परिषद

INDIAN COUNCIL OF MEDICAL RESEARCH

वी रासितगरवामी भवन अंसारी नगर, पे गारी 4911 नई दिल्ली 110020

V Ramalingaswami Bhawan, Ansari Nagar, P.B.No. 4911, New Delhi - 110029

वेतन और भत्ते खाते से परिषद के कर्मधारियों को वेतन एवं भत्तों के भ्यतान का कान

Payment of the pay & Allowances form to the	Council's employees from their pay & allowances a	ccounts
The pay a Alle Walles form to the	गान गं0/Reg.No	COUNTS /
ोता में /To,		14) 1
D- 10.		1

Dr. Vikaram Gota Scientific Officer-F Clinical Pharmacology

11/1 - best

Advanced Centre for Treatment Research and Education in Cancer Sector22,

Kharghar Navi Mumbai - 410210.

Acs/VI			New Delhi, The
बैंक की तारीख ank Date	राशि का ड्राफ्ट / चैक Draft/ Cheque Amount	बिलों का विवरण Particulars of Bills	रागि Amount
P1179	Adhoc/NCD	FB.	Rs.9,44,160/-

है / I amte forward herewith----- Demand Drafts/Cheques in payment of your bills details of which are given overleaf.

इस / इन बैंक ड्राफ्ट (ड्राफ्टों) / चैक (चैकों) की पावती वापसी डाक से भेज दी जाए अन्यथा परिषद मुख्यालय / संस्थान / केन्द्र के बिलों का भुगतान भविष्य में रोक दिया जाएगा /Receipt of the Bank Drafts/Cheques may kindly be acknowledged by return of post failing which payment of the future bills of our ICMR Hq./Instt./Centre is liable to be withheld

" बिलों के सत्वर भुगतान और उत्तर शीध ही पाने के लिए कृपया सभी बिलों और पत्रों के ऊपर पूरा पता और परिषद मुख्यालय / सस्थान / केन्द्र का नाम লিউ । " " To ensure prompt of bills and reply, please state full address and name of ICMR Hq./Instt./Centre on all bills and correspondence. "

> भवदीय/ Yours faithfully. कृते लेखा अधिकारी/ For Accounts Office

File No.5/13/73/2013-NCD-III

विवरण संख्या / STATEMENT NO.

मांग संख्या /Reg.No.....

मद सं0./I.No.....

सेवा में/ To.

लेखा अधिकारी/ The Accounts Officer,

भारतीय आयुर्विज्ञान अनुसंधान परिषद/Indian Council of Medical Research,

नई दिल्ली - 110029/ New Delhi- 110029

विषय/Subject : बिलों का भुगतान/ Payment of bills

महोदय/ Sir. आपके दिनांकके पत्र सं. ए सी / बिल सं. के संदर्भ में रुपये का बैंक ड्राफ्ट / चैक सं0 दिनांककी पावती भेजी जाती है। With reference to your letter No. AC/Bills----dated ----- Receipt of Bank Drafts/Cheques No. ----- Dated ----- for Rs. ---------is acknowledge.

भवदीय/ Yours faithfully,

No 5/13/73/2013-NCD-III

Tur 1 4/8/14

Subject: Payment of 1st year Full & Final Instalment of grant-in-aid for the research scheme entitled "Preclinical Pharmacokinetics and I fficacy Study of the 3 Anticancer Drug – MCr – 34° thder Dr. Vikaram Gota, Scientific Officer-F. Clinical Pharmacology Advanced Centre for Treatment Research and Education in Cancer (TMC) Sector 22, Kharghar, Navi Mumbai – 410210.

MEMORIANDUM:

Reference this office letter No. 5/13/73/2008-NCD-III

Dated

Director-General, ICMR sanctions payment of Rs.9,44,160/- (Rupees Nine lakhs—Forty for incurring expenditure in connection with the above mentioned research Scheme. The amount of Rs.9,44,160/- may be debited in the provision of Rs.9,44,160/- made for the above mentioned research scheme for the above mentioned research scheme for the current financial year 2014-2015.

A Formal bill for Rs 9,44,160/- is sent herewith for payment by cheque/demand draft for Rs.4,22,800/-for payment to The Advanced Centre for Treatment Research and Education Cancer (TMC) Sector 22, Kharghar, Navi Mumbai – 410210.

(Sushia Kargaonkar) Sr. Admin. Officer For Director-General.

Accounts Section, VICMR, RFC No.NCD/ad-hoc/05/2014-2015 Dt. 27.07-2014

Copy to: 1. Vikaram Gota. Scientific Officer-F. Clinical Pharmacology. Advanced Centre for Treatment. Research and Education in Cancer (TMC) Sector 22, Kharghar, Navi Mumbai – 410210. A Bank draft/cheque for the amount of Rs.9,44,161/2 will be sent to you in due course. The grant has been sanctioned on the conditions laid down in our letter referred to above.

2.The Director Advanced Centre for Treatment Research and Education in Cancer (TMC) Sector 22, Kharghar, Navi Mumbai – 410210

3.IRIS No. (2013- 20120) (P&I) Section, ICMR

4. Sr. Administrative Officer,

gus LVs

For Director General.

COUNCIL OF SCIENTIFIC AND INDUSTRIAL KESEAR

EXTRAMURAL RESEARCH DIVISION - II

CID	COMPI
7115.	R. R. SIVIET

(Opt.	Instit	ute of	Hote	Mana	igem
Library	AV	enue,	Pusa,	New	Delhi	110

No 27 (271) /12-EMR-17 From:

Head (HRDG)

Dr Manoj B Mahimkar ACTREC, Tata Memorial CTR.
Navi Munibar- 410208 (Mahasashtsen)

Sub: Renewal of grants for scheme on " & enomic + - - - cencer. Sir,

The Director-General, Scientific & Industrial Research, has been pleased to sanction renewal of above scheme with the following grants for the period from .1.4/2012. to 31/.3.1.2014

a. Staff:

b. Contingency:

c. Equipment:

Rs. 8,00,000/-Rs. ----

Rs. Broom/

- This grant is subject to the terms and conditions on which the scheme was origin sanctioned and as modified from time to time.
- 2. Bill in triplicate in enclosed Performa claiming grant sanctioned may please through the appropriate authority of your institution after complying with formalities required under the rules. The position regarding unspent balance of previous year's grants must be clearly mentioned head-wise in the bill failing v it may be returned Unpassed for compliance.
- particulars of Staff working in the scheme i.e. his name, Fellov (JRF/SRF/RA)held, date of joining resignation etc. for whom claim under "Staff" is made should invariably mentioned in the bill.
- 4. The expenditure is debatable to budget head "Special Research Progran Extramural Research Grants! (Res. Schemes).

No.PS: The grant will be sent to you through RBI-EFT (Electronic Funds Transfer), to the concerned authority of your institution on receipt of BFT Transfer Request Form (Enclosed), Utilization Certificate and Statement of accounts which may please be sent along the Claim Bill.

D) Subject to DOC

Yours faithfully

Encl. As above

Copy to: The Director ACT REC

The statement of accounts duly audited by the Accounts Officer and counter-signed by the higher authority in respect of grants received & expenditure incurred during previous year sho sent to this office with the bill claiming grants for the above period.

Your attention is drawn to the rule No.0.3 of the Terms & Condition of CSIR Research

booklet.